id
stringlengths 14
14
| page_content
stringlengths 10
2.06k
| source
stringclasses 1
value |
|---|---|---|
0c456b87884d-2 | Arlene I. Lev, M.S.W., L.C.S.W.-R
Gregory K. Lewis, M.A.-L.M.F.T.
Jane Hart Lewis, M.S.
Melissa S. Lewis, M.S.W., L.I.C.S.W.
Norman Gerald Lewis, F.R.A.N.Z.C.P.
Robin Joy Lewis, Ph.D.
Ryan Michael Ley, M.D.
Tammy R. Lias, M.A.
Russell F. Lim, M.D.
Jana Lincoln, M.D.
Ted Lindberg, L.M.S.W., L.M.F.T., M.S.W.
Peggy Solow Liss, M.S.W.
Andrea Loeb, Psy.D.
William David Lohr, M.D.
Mary L. Ludy, M.A., L.M.H.C., L.M.F.T.
Nathan Lundin, M.A., L.P.C.
Veena Luthra, M.D.
Patti Lyerly, L.C.S.W.
Denise E. Maas, M.A.
Silvia MacAllister, L.M.F.T.
Nicola MacCallum, M.S., M.F.C. Therapy
Colin N. MacKenzie, M.D.
Cynthia Mack-Ernsdorff, Ph.D.
John R. Madsen-Bibeau, M.S., M.Div
Christopher J. Maglio, Ph.D.
Deepak Mahajan, M.D.
Debra Majewski, M.A.
Harish Kumar Malhotra, M.D.
Pamela Marcus, R.N., M.S.
Mary P. Marshall, Ph.D.
Flora Lynne Martin, M.A., L.P.C., A.D.C.
Robert S. Martin, M.D.
Jennifer L. Martinez, M.S. | dsm5.pdf |
0c456b87884d-3 | Robert S. Martin, M.D.
Jennifer L. Martinez, M.S.
Ninfa Martinez-Aguilar, M.A., M.F.T.
Emily Martinsen, M.S.W.
Farhan A. Matin, M.D.
Janus Maybee, P.M.H.N.P.
Karen Mazarin-Stanek, M.A.
Eben L. McClenahan, M.D., M.S.
Jerlyn C. McCleod, M.D.
Susan E. McCue, M.S.W., L.C.S.W.
Kent D. McDonald, M.S.
Daniel McDonnell, M.S.N, P.M.H.-N.P.
Robert McElhose, Ph.D.
Lisa D. McGrath, Ph.D.
Mark McGrosky, M.S.W.
Katherine M. McKay, Ph.D.
Darren D. McKinnis, M.S.W.
Mona McNelis-Broadley, M.S.W., L.C.S.W.
Rick McQuistion, Ph.D.
Susan Joy Mendelsohn, Psy.D.
Barbara S. Menninga, M.Ed.
Hindi Mermelstein, M.D., F.A.P.M.
Rachel B. Mich aelsen, M.S.W. | dsm5.pdf |
547003e97325-0 | DSM-5 Advisors and Other Contributors 915
Thomas F. Micka, M.D.
Tonya Miles, Psy.D.
Matthew Miller, M.S.
Michael E. Miller, M.D.
Noel Miller, L.M.S.W., M.B.A., M.P.S.
Kalpana Miriyala, M.D.
Sandra Moenssens, M.S.
Erin Mokhtar, M.A.
Robert E. Montgomery, M.Ed.
Susan Moon, M.A.
Theresa K. Moon, M.D.
David B. Moore, B.A., M.Div., M.S.S.W., Ph.D.
Joanne M. Moore, M.S.
Peter I. M. Moran, M.B.B.Ch.
Anna Moriarty, M.P.S., L.P.C., L.M.H.C.
Richard Dean Morris, M.A.
Michael M. Morrison, M.A.
Carlton E. Munson, Ph.D.
Timothy A. Murphy, M.D.
Beth L. Murphy, Psy.D.
Melissa A. Myers, M.D.
Stefan Nawab, M.D.
Allyson Matney Neal, D.N.P.
Steven Nicholas, M.A.
Aurelian N. Niculescu, M.D.
Earl S. Nielsen, Ph.D.
Terry Oleson, Ph.D.
Julianne R. Oliver, B.S., M.S., Ph.D.
Robert O. Olsen, M.D.
Amy O'Neill, M.D.
Oscar H. Oo, Psy.D., A.B.P.P.
Laurie Orlando, J.D., M.A.
Jill Osborne, M.S., Ed.S.
Kimberly Overlie, M.S.
L. Kola Oyewumi, Ph.D. | dsm5.pdf |
547003e97325-1 | L. Kola Oyewumi, Ph.D.
Zachary J. Pa cha, M.S.W.
Suzette R. Papadakis, M.S.
Amanda C. Parsons, M.A., L.P.C.C.
Lee R. Pate, B.A., M.A.
Eric L. Patterson, L.P.C.
Sherri Paulson, M.Ed., L.S.C.W.
Peter Dennis Pautz, B.A., M.S.W.
Malinda J. Perkins, M.S.W., L.C.S.W.
Eleanor F. Perlman, M.S.W.
Deborah K. Perry, M.S.W.
Amanda Peterman, L.M.F.T.
Shawn Pflugardt, Psy.D.
Robert J. Dean Phillips, M.S.
Laura Pieper, M.S.W., L.C.S.W.
Lori D. Pink, M.S.W., B.C.D
Michael G. Pipich, M.S., L.M.F.T.
Cynthia G. Pizzulli, M.S.W., Ph.D.
Kathy C. Points, M.A.
Marya E. Pollack, M.D., M.P.H.
Sanford E. Pomerantz, M.D.
Eva Ponder, M.S.W., Psy.D.
Ernest Poortinga, M.D.
David Post, M.D.Laura L. Post, M.D., Ph.D., J.D.
Patrick W. Powell, Ed.D.
Beth M. Prewett, Psy.D.
Robert Price, D.C.C., M.Ed.
John Pruett, M.D.
Aneita S. Radov, M.A.
Dawn M. Raffa, Ph.D.
Kavitha Raja, M.D. | dsm5.pdf |
547003e97325-2 | Kavitha Raja, M.D.
Ranjit Ram, M.D.
Mohamed Ibrahim Ramadan, M.D., M.S.
Christopher S. Randolph, M.D.
Nancy Rappaport, M.Ed.
John Moir Rauenhorst, M.D.
Laurel Jean Rebenstock, L.M.S.W.
Edwin Renaud, Ph.D.
Heather J. Rhodes, M.A.
Jennifer S. Ritchie-Goodline, Psy.D.
Daniel G. Roberts, M.A.
Brenda Rohren, M.A., M.F.S., L.I.M.H.P.,
L.A.D.C., M.A.C.
Donna G. Rolin-Kenny, Ph.D., A.P.R.N.,
P.M.H.C.N.S.-B.C.
Sylvia E. Rosario, M.Ed.
Mindy S. Rosenbloom, M.D.
Harvey A. Rosenstock, M.D.
Thalia Ross, M.S.S.W.
Fernando Rosso, M.D.
Barry H. Roth, M.D.
Thomas S. Rue, M.A., L.M.H.C.
Elizabeth Ruegg, L.C.S.W.
Diane Rullo, Ph.D.
Angie Rumaldo, Ph.D.
Eric Rutberg, M.A., D.H.Ed.
Joseph A. Sabella, L.M.H.C.
Kemal Sagduyu, M.D.
Adam H. Saltz, M.S.W.
Jennifer A. Samardak, L.I.S.W.-S.
George R. Samuels, M.A., M.S.W.
Carmen Sanjurjo, M.A.
John S. Saroyan, Ed.D.
Brigid Kathleen Sboto, M.A., M.F.T. | dsm5.pdf |
547003e97325-3 | Brigid Kathleen Sboto, M.A., M.F.T.
Lori Cluff Schade, M.S.
Joan E. Schaper, M.S.N.
Rae J. Schilling, Ph.D.
Larry Schor, Ph.D.
Donna J. Schwartz, M.S.W., L.I.C.S.W.
Amy J. Schwarzenbart, P.M.H.-C.N.S., B.C.,
A.P.N.P.
John V. Scialli, M.D.
Chad Scott, Ph.D., L.P.C.C.
Sabine Sell, M.F.T.
Minal Shah, N.S., N.C.C., L.P.C.
Lynn Shell, M.S.N.
Dharmesh Navi n Sheth, M.D.
S. Christopher Shim, M.D.
Marta M. Shinn, Ph.D.
Andreas Sidiropoulos, M.D., Ph.D.
Michael Siegell, M.D. | dsm5.pdf |
a06419415e85-0 | 916 DSM-5 Advisors and Other Contributors
Michael G. Simonds, Psy.D.
Gagandeep Singh, M.D.
Melissa Rae Skrzypchak, M.S.S.W., L.C.S.W.
Paula Slater, M.D.
William Bill Slaughter, M.D., M.A.
Aki Smith, Ph.D.
Deborah L. Smith, Ed.M.
Diane E. Smith, M.A., L.M.F.T.
James S. Sommer, M.S.
J. Richard Spatafora, M.D.
Judy Splittgerber, M.S.N., C.S., N.P.
Thiruneermalai T.G. Sriram, M.D.
Martha W. St. John, M.D.
Sybil Stafford, Ph.D.
Timothy Stambaugh, M.A.
Laura A. Stamboni, M.S.W.
Carol L. R. Stark, M.D.
Stephanie Steinman, M.S.
Claudia M. Stevens, M.S.W.
Jennifer Boyer Stevens, Psy.D.
Dominique Stevens-Young, M.S.W., L.C.S.W.
Kenneth Stewart, Ph.D.
Daniel Storch, M.D.
Suzanne Straebler, A.P.R.N.
Dawn Stremel, M.A., L.M.F.T.
Emel Stroup, Psy.D.
John W. Stump, M.S., L.M.F.T.
Thomas G. Suk, M.A.
Elizabeth Sunzeri, M.S.
Linnea Swanson, M.A., Psy.D.
Patricia Swanson, M.A.
Fereidoon Taghizadeh, M.D. | dsm5.pdf |
a06419415e85-1 | Fereidoon Taghizadeh, M.D.
Bonnie L. Tardif, L.M.H.C., N.C.C., B.C.P.C.C.
Joan Tavares, M.S.W.
Ann Taylor, M.S.W.
Dawn O'Dwyer Taylor, Ph.D.
Chanel V. Tazza, L.M.H.C.
Martha H. Teater, M.A.
Clark D. Terrell, M.D.
Mark R. Thelen, Psy.D.
Norman E. Thibault, M.S., Ph.D.
Tojuana L. Thomason, Ph.D.
Paula Thomson, Psy.D.
D. Chadwick Thompson, M.A.
Susan Thorne-Devin, A.M.
Jean Eva Thumm, M.A.P.C., M.A.T., L.M.F.T.,
B.C.C.
James E. Tille, Ph.D., D.Min.
Jacalyn G. Tippey, Ph.D.
Saraswathi Tirumalasetty, M.D.
Jacqueline A. Torrance, M.S.
Terrence Trobaugh, M.S.
Louisa V. Troemel, Psy.D., L.M.F.T.Susan Ullman, M.S.W.
Jennifer M. Underwood, M.S.W., L.C.S.W.
Rodney Dale Veldhuizen, M.A.
Michelle Voegels, B.S.N., M.S.N., B.C.
Wess Vogt, M.D.
R. Christopher Votolato, Psy.D.
John W. Waid, Ph.D.
Christa A. Wallis, M.A.
Dominique Walmsley, M.A.
Bhupinder Singh Waraich, M.D. | dsm5.pdf |
a06419415e85-2 | Bhupinder Singh Waraich, M.D.
Joseph Ward, N.C.C., L.P.C. M.Ed.
Robert Ward, M.S.W.
Marilee L. M. Wasell, Ph.D.
Gannon J. Watts, L.P.C.-S., L.A.C., N.C.C.,
N.C.S.C., A.A.D.C., I.C.A.A.D.C.
Sheila R. Webster, M.A., M.S.S.A.
Burton Weiss, M.D.
Dennis V. Weiss, M.D.
Jonathan S. Weiss, M.D.
Richard Wendel, Ph.D.
Paul L. West, Ed.D.
Kris Sandra Wheatley, M.A., L.P.C., N.C.C.
Leneigh White, M.A.
Danny R. Whitehead, L.I.C.S.W.
Jean Whitinger, M.A.
Peter D. Wilk, M.D.
Vanessa Wilkinson, L.P.C.
Tim F. Willia, M.S., M.A.Ed., L.P.C.
Cathy E. Willis, M.A., L.M.F.T., C.A.D.C.
Jeffery John Wilson, M.D.
Jacquie Wilson, M.Ed.
David D. Wines, M.S.W.
Barbara A. Wirebaugh, M.S.W.
Daniel L. Wise, Ph.D.
Christina Wong, M.S.W., L.C.S.W.
Susanna Wood, M.S.W., L.C.S.W.
Linda L. Woodall, M.D.
Leoneen Woodard-Faust, M.D.
Sheryl E. Woodhouse, L.M.F.T.
Gregory J. Worthington, Psy.D.
Tanya Wozniak, M.D. | dsm5.pdf |
a06419415e85-3 | Tanya Wozniak, M.D.
Kimberly Isaac Wright, M.A.
Peter Yamamoto, M.D.
Maria Ruiza Ang Yee, M.D.
Michael B. Zafrani, M.D.
Jafet E. Gonzalez Zakarchenco, M.D.
John Zibert, Ph.D.
Karen Zilberstein, M.S.W.
Cathi Zillmann, C.P.N.P., N.P.P.
Gerald A. Zimmerman, Ph.D.
Michele Zimmerman, M.A., P.M.H.C.N.S.-B.C.
Judith A. Zink, M.A.
Vanderbilt University REDCap Team
Paul Harris, Ph.D.
Sudah Kashyap, B.E.
Brenda MinorJon Scherdin, M.A.
Rob Taylor, M.A.
Janey Wang, M.S. | dsm5.pdf |
0e9f5f166e70-0 | 917Index
Page numbers printed in boldface type refer to tables.
Abuse and neglect, 22, 717–722
adult maltreatment and neglect problems,
720–722
child maltreatment and neglect problems,
717–719
Access to medica l and other health care, problems
related to, 726
Acute dissociative reacti ons to stressful events,
306–307
Acute stress disorder, 265, 280–286
associated features supporting diagnosis of,
283–284
culture-related diagnostic issues in, 285
development and course of, 284
diagnostic criteria for, 280–281
diagnostic features of, 281–283
differential diagnosis of, 285–286
functional consequences of, 285
gender-related diagnostic issues in, 285
prevalence of, 284
risk and prognostic factors for, 284–285
Addiction. See Substance-related and addictive
disorders
ADHD. See Attention-deficit/hyperactivity
disorder
Adjustment disorders, 265, 286–289
comorbidity with, 289
culture-related diagnostic issues in, 288
development and course of, 287
diagnostic criteria for, 286–287
diagnostic features of, 287
differential diagnosis of, 288–289
functional consequences of, 288
prevalence of, 287
risk and prognostic factors for, 288
Adjustment-like disorders, 289
Adult maltreatment and neglect problems, 720–
722
adult abuse by nonspouse or nonpartner, 722
spouse or partner abuse, psychological, 721–
722
spouse or partner neglect, 721
spouse or partner violence, physical, 720 | dsm5.pdf |
0e9f5f166e70-1 | spouse or partner neglect, 721
spouse or partner violence, physical, 720
spouse or partner violence, sexual, 720Agoraphobia, 190, 217–221
associated features supporting diagnosis of,
219
comorbidity with, 221
development and course of, 219–220
diagnostic criteria for, 217–218
diagnostic features of, 218–219
differential diagnosis of, 220–221
functional consequences of, 220
gender-related diagnostic issues in, 220
prevalence of, 219
risk and prognostic factors for, 220
Akathisia, medication-induced, 22
acute, 711
tardive, 712
Alcohol intoxication, 497–499
associated features supporting diagnosis of,
497–498
comorbidity with, 499
culture-related diagnostic issues in, 498
development and course of, 498
diagnostic criteria for, 497
diagnostic features of, 497
diagnostic markers for, 499
differential diagnosis of, 499
functional consequences of, 499
gender-related diagnostic issues in, 498
prevalence of, 498
risk and prognostic factors for, 498
Alcohol-related disorders, 481, 490–503
alcohol intoxication, 497–499
alcohol use disorder, 490–497
alcohol withdrawal, 484, 499–501
diagnoses associated with, 482
other alcohol-induced disorders, 502–503
development and course of, 502–503
features of, 502
unspecified alcohol-related disorder, 503
Alcohol use disorder, 490–497
associated features supporting diagnosis of,
492–493
comorbidity with, 496–497 | dsm5.pdf |
0e9f5f166e70-2 | 492–493
comorbidity with, 496–497
culture-related diagnostic issues in, 494–495
development and course of, 493–494 | dsm5.pdf |
33599eeb10ab-0 | 918 Index
Alcohol use disorder (continued)
diagnostic criteria for, 490–491
diagnostic features of, 492
diagnostic markers for, 495–496
differential diagnosis of, 496
functional consequences of, 496
prevalence of, 493
risk and prognostic factors for, 494
specifiers for, 492
Alcohol withdrawal, 499–501
associated features supporting diagnosis of, 500
comorbidity with, 501
development and course of, 501
diagnostic criteria for, 499–500
diagnostic features of, 500
diagnostic markers for, 501
differential diagnosis of, 501
functional consequences of, 501
prevalence of, 501
risk and prognostic factors for, 501
specifiers for, 500
Alzheimer’s disease, major or mild
neurocognitive disorder due to, 591, 603,
611–614
associated features supporting diagnosis of, 612
comorbidity with, 614
culture-related diagnostic issues in, 613
development and course of, 612–613
diagnostic criteria for, 611–612
diagnostic features of, 612
diagnostic markers for, 613
differential diagnosis of, 614
functional consequences of, 614
prevalence of, 612
risk and prognostic factors for, 613
American Psychiatric Association (APA), 5–7
Anorexia nervosa, 329, 338–345
associated features supporting diagnosis of, 341
atypical, 353
comorbidity with, 344–345
culture-related diagnostic issues in, 342
development and course of, 341–342
diagnostic criteria for, 338–339
diagnostic features of, 339–340 | dsm5.pdf |
33599eeb10ab-1 | diagnostic criteria for, 338–339
diagnostic features of, 339–340
diagnostic markers for, 342–343
differential diagnosis of, 344
functional consequences of, 343
prevalence of, 341
risk and prognostic factors for, 342
subtypes of, 339
suicide risk in, 343
Antidepressant discontinuation syndrome, 22,
712–714
comorbidity with, 714
course and development of, 713diagnostic features of, 713
differential diagnosis of, 713–714
prevalence of, 713
Antisocial personality disorder, 461, 476, 645, 646,
659–663
associated features supporting diagnosis of,
660–661
culture-related diagnostic issues in, 662
development and course of, 661
diagnostic criteria for, 659
diagnostic features of, 659–660
differential diagnosis of, 662–663
features and criteria in alternative DSM-5
model for personality disorders, 763,
764–765
gender-related diagnostic issues in, 662
prevalence of, 661
risk and prognostic factors for, 661–662
Anxiety disorder due to another medical
condition, 190, 230–232
associated features supporting diagnosis of,
231
development and course of, 231
diagnostic criteria for, 230
diagnostic features of, 230–231
diagnostic markers for, 231
differential diagnosis of, 231–232
prevalence of, 231
Anxiety disorders, 189–264
agoraphobia, 190, 217–221
anxiety disorder due to another medical
condition, 190, 230–232 | dsm5.pdf |
33599eeb10ab-2 | anxiety disorder due to another medical
condition, 190, 230–232
generalized anxiety disorder, 190, 222–226
highlights of changes fr om DSM-IV to DSM-5,
811
other specified anxiety disorder, 233
panic attack specifier, 214–217
panic disorder, 190, 208–214
selective mutism, 189, 195–197
separation anxiety disorder, 189, 190–195
social anxiety disorder (social phobia), 190,
202–208
specific phobia, 189–190, 197–202
substance/medication-induced anxiety
disorder, 190, 226–230
unspecified anxiety disorder, 233
APA (American Psychiatric Association), 5–7
Assessment measures, 23–24, 733–748
cross-cutting symptom measures, 733–741
DSM-5 Level 1 Cross-Cutting Symptom
Measure, 734–736, 738–741
DSM-5 Level 2 Cross-Cutting Symptom
Measures, 734, 735, 736, 737
frequency of use of, 737
severity measures, 733, 742 | dsm5.pdf |
6ac6fc95c202-0 | Index 919
Clinician-Rated Dimensions of Psychosis
Symptom Severity, 742–744
frequency of use of, 742
scoring and interpretation of, 742
WHO Disability Assessment Schedule
(WHODAS), 16, 21, 734, 745–748
Ataque de nervios, 14, 211–212, 233, 833
Attention-deficit/hyperactivity disorder
(ADHD), 11, 32, 59–66
associated features supporting diagnosis of, 61
comorbidity with, 65
culture-related diagnostic issues in, 62
development and course of, 61
diagnostic criteria for, 59–61
diagnostic features of, 61
differential diagnosis of, 63–65
functional consequences of, 63
gender-related diagnostic issues in, 63
medication-induced symptoms of, 65
other specified attentio n-deficit/hyperactivity
disorder, 65–66
prevalence of, 61
risk and prognostic factors for, 62
unspecified attention- deficit/hyperactivity
disorder, 66
Attenuated psychosis syndrome, 122, 783–786
associated features supporting diagnosis of, 784
comorbidity with, 786
development and course of, 785
diagnostic features of, 783–784
differential diagnosis of, 785–786
functional consequences of, 785
prevalence of, 784–785
proposed criteria for, 783
risk and prognostic factors for, 785
Autism spectrum disorder, 31–32, 50–59
associated features supporting diagnosis of, 55
comorbidity with, 58–59
culture-related diagnostic issues in, 57
development and course of, 55–56 | dsm5.pdf |
6ac6fc95c202-1 | culture-related diagnostic issues in, 57
development and course of, 55–56
diagnostic criteria for, 50–51
diagnostic features of, 53–55
differential diagnosis of, 57–58
functional consequences of, 57
gender-related diagnostic issues in, 57
prevalence of, 55
recording procedures for, 51
risk and prognostic factors for, 56–57
specifiers for, 51–53, 52
Avoidant personality disorder, 645, 646, 672–675
associated features supporting diagnosis of,
673–674
culture-related diagnostic issues in, 674
development and course of, 674
diagnostic criteria for, 672–673diagnostic features of, 673
differential diagnosis of, 674–675
features and criteria in alternative DSM-5
model for personality disorders, 763,
765–766
gender-related diagnostic issues in, 674
prevalence of, 674
Avoidant/restrictive food intake disorder, 329,
334–338
associated features supporting diagnosis of, 335
comorbidity with, 338
culture-related diagnostic issues in, 336
development and course of, 335–336
diagnostic criteria for, 334
diagnostic features of, 334–335
diagnostic markers for, 336
differential diagnosis of, 336–338
functional consequences of, 336
gender-related diagnostic issues in, 336
risk and prognostic factors for, 336
Bereavement, 125–126, 134, 155, 161, 194
persistent complex, 289, 789–792
Binge-eating disorder, 329, 350–353
associated features supporting diagnosis of, 351 | dsm5.pdf |
6ac6fc95c202-2 | associated features supporting diagnosis of, 351
comorbidity with, 353
culture-related diagnostic issues in, 352
development and course of, 352
diagnostic criteria for, 350
diagnostic features of, 350–351
differential diagnosis of, 352–353
functional consequences of, 352
of low frequency and/or limited duration, 353
prevalence of, 351
risk and prognostic factors for, 352
Bipolar I disorder, 123–132
associated features supporting diagnosis of, 129
comorbidity with, 132
culture-related diagnostic issues in, 130
development and course of, 130
diagnostic criteria for, 123–127
diagnostic features of, 127–129
differential diagnosis of, 131–132
functional consequences of, 131
gender-related diagnostic issues in, 130
prevalence of, 130
risk and prognostic factors for, 130
suicide risk and, 131
Bipolar II disorder, 123, 132–139
associated features supporting diagnosis of, 136
comorbidity with, 139
development and course of, 136–137
diagnostic criteria for, 132–135
diagnostic features of, 135–136
differential diagnosis of, 138–139 | dsm5.pdf |
ed4791512826-0 | 920 Index
Bipolar II disorder (continued)
functional consequences of, 138
gender-related diagnostic issues in, 137
prevalence of, 136
risk and prognostic factors for, 137
suicide risk in, 138
Bipolar and related disorder due to another
medical condition, 123, 145–147
associated features supporting diagnosis of, 146
comorbidity with, 147
culture-related diagnostic issues in, 147
development and course of, 146–147
diagnostic criteria for, 145–146
diagnostic features of, 146
diagnostic markers for, 147
differential diagnosis of, 147
functional consequences of, 147
gender-related diagnostic issues in, 147
Bipolar and related disorders, 123–154
bipolar I disorder, 123–132
bipolar II disorder, 123, 132–139
bipolar and related disorder due to another
medical condition, 123, 145–147
cyclothymic disorder, 123, 139–141
highlights of changes fr om DSM-IV to DSM-5,
810
other specified bipolar and related disorder,
123, 148
specifiers for, 149–154
substance/medication-induced bipolar and
related disorder, 123, 142–145
unspecified bipolar and related disorder, 149
Body dysmorphic disorder, 235, 236, 242–247
associated features supporting diagnosis of, 244
comorbidity with, 247
culture-related diagnostic issues in, 245
development and course of, 244
diagnostic criteria for, 242–243
diagnostic features of, 243–244
differential diagnosis of, 245–247
functional consequences of, 245 | dsm5.pdf |
ed4791512826-1 | differential diagnosis of, 245–247
functional consequences of, 245
gender-related diagnostic issues in, 245
prevalence of, 244
risk and prognostic factors for, 245
suicide risk and, 245
Body dysmorphic-like disorder with actual flaws,
263
Body dysmorphic-like disorder without repetitive
behaviors, 263
Body-focused repetitive behavior disorder, 235,
263–264
Borderline personality disorder, 645, 646, 663–666
associated features supporting diagnosis of, 665
culture-related diagnostic issues in, 665–666
development and course of, 665diagnostic criteria for, 663
diagnostic features of, 663–664
differential diagnosis of, 666
features and criteria in alternative DSM-5
model for personality disorders, 763,
766–767
gender-related diagnostic issues in, 666
prevalence of, 665
risk and prognostic factors for, 665
Breathing-related sleep disorders, 361, 378–390
central sleep apnea, 383–386
obstructive sleep ap nea hypopnea, 378–383
sleep-related hypoventilation, 387–390
Brief illness anxiety disorder, 327
Brief psychotic disorder, 94–96
associated features supporting diagnosis of, 95
culture-related diagnostic issues in, 95
development and course of, 95
diagnostic criteria for, 94
diagnostic features of, 94–95
differential diagnosis of, 96
duration of, 89, 94, 99
functional consequences of, 95
prevalence of, 95
risk and prognostic factors for, 95
Brief somatic symptom disorder, 327 | dsm5.pdf |
ed4791512826-2 | risk and prognostic factors for, 95
Brief somatic symptom disorder, 327
Bulimia nervosa, 329, 345–350
associated features supporting diagnosis of, 347
comorbidity with, 349–350
culture-related diagnostic issues in, 348
development and course of, 347–348
diagnostic criteria for, 345
diagnostic features of, 345–347
diagnostic markers for, 348
differential diagnosis of, 349
functional consequences of, 349
gender-related diagnostic issues in, 348
of low frequency and/or limited duration, 353
prevalence of, 347
risk and prognostic factors for, 348
suicide risk in, 349
Caffeine intoxication, 503–506
associated features supporting diagnosis of, 504
comorbidity with, 506
development and course of, 505
diagnostic criteria for, 503–504
diagnostic features of, 504
differential diagnosis of, 505
functional consequences of, 505
prevalence of, 505
risk and prognostic factors for, 505
Caffeine-related disorders, 481, 503–509
caffeine intoxication, 503–506
caffeine withdrawal, 506–508 | dsm5.pdf |
12149abe69d2-0 | Index 921
diagnoses associated with, 482
other caffeine-indu ced disorders, 508
unspecified caffeine- related disorder, 509
Caffeine use disorder, 792–795
comorbidity with, 795
development and course of, 794
diagnostic features of, 793–794
differential diagnosis of, 795
functional consequences of, 794–795
prevalence of, 794
proposed criteria for, 792–793
risk and prognostic factors for, 794
Caffeine withdrawal, 506–508
associated features supporting diagnosis of, 507
comorbidity with, 508
culture-related diagnostic issues in, 508
development and course of, 507
diagnostic criteria for, 506
diagnostic features of, 506–507
differential diagnosis of, 508
functional consequences of, 508
prevalence of, 507
risk and prognostic factors for, 507–508
Cannabis intoxication, 516–517
diagnostic criteria for, 516
diagnostic features of, 516–517
differential diagnosis of, 517
functional consequences of, 517
prevalence of, 517
specifiers for, 516
Cannabis-related disorders, 481, 509–519
cannabis intoxication, 516–517
cannabis use disorder, 509–516
cannabis withdrawal, 484, 517–519
diagnoses associated with, 482
other cannabis-induced disorders, 519
unspecified cannabis-related disorder, 519
Cannabis use disorder, 509–516
associated features supporting diagnosis of, 512
comorbidity with, 515–516
culture-related diagnostic issues in, 514
development and course of, 513 | dsm5.pdf |
12149abe69d2-1 | culture-related diagnostic issues in, 514
development and course of, 513
diagnostic criteria for, 509–510
diagnostic features of, 510–512
diagnostic markers for, 514
functional consequences of, 514–515
prevalence of, 512
risk and prognostic factors for, 513–514
specifiers for, 510
Cannabis withdrawal, 517–519
development and course of, 518
diagnostic criteria for, 517–518
diagnostic features of, 518
differential diagnosis of, 519
risk and prognostic factors for, 519Case formulation, 19–20
cultural, 749–759 ( See also Cultural
formulation)
Catatonia, 89, 119–121
associated with another mental disorder
(catatonia specifier), 119–120
diagnostic criteria for, 119–120
diagnostic features of, 120
unspecified, 89, 121
Catatonic disorder due to another medical
condition, 120–121
associated features supporting diagnosis of, 121
diagnostic criteria for, 120–121
diagnostic features of, 121
differential diagnosis of, 121
Central sleep apnea, 383–386
associated features supporting diagnosis of, 385
comorbidity with, 386
development and course of, 385
diagnostic criteria for, 383–384
diagnostic features of, 384–385
diagnostic markers for, 385
differential diagnosis of, 386
functional consequences of, 386
prevalence of, 385
risk and prognostic factors for, 385
specifiers for, 384
subtypes of, 384
CFI. See Cultural Formulation Interview | dsm5.pdf |
12149abe69d2-2 | subtypes of, 384
CFI. See Cultural Formulation Interview
Cheyne-Stokes breathing, 383–386. See also Central
sleep apnea
Childhood-onset fluency di sorder (stuttering), 31,
45–47
associated features supporting diagnosis of, 46
development and course of, 46–47
diagnostic criteria for, 45–46
diagnostic features of, 46
differential diagnosis of, 47
functional consequences of, 47
risk and prognostic factors for, 47
Child maltreatment and neglect problems, 717–719
child neglect, 718–719
child physical abuse, 717–718
child psychological abuse, 719
child sexual abuse, 718
Circadian rhythm sleep-wake disorders, 361,
390–398
advanced sleep phase type, 393–394
associated features supporting diagnosis
of, 393
comorbidity with, 394
culture-related diagnostic issues in, 394
development and course of, 393
diagnostic features of, 393
diagnostic markers for, 394 | dsm5.pdf |
98ad50f7b918-0 | 922 Index
Circadian rhythm sleep-wake disorders
(continued)
advanced sleep phase type (continued)
differential diagnosis of, 394
functional consequences of, 394
prevalence of, 393
risk and prognostic factors for, 394
specifiers for, 393
delayed sleep phase type, 391–392
associated features supporting diagnosis
of, 391
comorbidity with, 392
development and course of, 391
diagnostic features of, 391
diagnostic markers for, 392
differential diagnosis of, 392
functional consequences of, 392
prevalence of, 391
risk and prognostic factors for, 392
diagnostic criteria for, 390–391
irregular sleep-wake type, 394–396
associated features supporting diagnosis
of, 395
comorbidity with, 396
development and course of, 395
diagnostic features of, 394–395
diagnostic markers for, 395
differential diagnosis of, 395
functional consequences of, 395
prevalence of, 395
risk and prognostic factors for, 395
non-24-hour sleep-wake type, 396–397
associated features supporting diagnosis
of, 396
comorbidity with, 397
development and course of, 396
diagnostic features of, 396
diagnostic markers for, 397
differential diagnosis of, 397
functional consequences of, 397
prevalence of, 396
risk and prognostic factors for, 396–397
relationship to International Classification of
Sleep Disorders, 398
shift work type, 397–398
comorbidity with, 398
development and course of, 398
diagnostic features of, 397 | dsm5.pdf |
98ad50f7b918-1 | development and course of, 398
diagnostic features of, 397
diagnostic markers for, 398
differential diagnosis of, 398
functional consequences of, 398
prevalence of, 397
risk and prognostic factors for, 398
Clinician-Rated Dimensions of Psychosis
Symptom Severity, 742–744Coding and reporting procedures, 12, 16, 22, 23,
29
Cognitive disorders. See Neurocognitive disorders
Communication disorders, 31, 41–49
childhood-onset fluency disorder (stuttering),
45–47
language disorder, 42–44
social (pragmatic) communication disorder,
47–49
speech sound disorder, 44–45
unspecified communication disorder, 49
Comorbidity, 5
Compulsions, 235–236, 239. See also Obsessive-
compulsive and related disorders
Conditions for further study, 7, 11, 24, 783–806
attenuated psychosis syndrome, 783–786
caffeine use disorder, 792–795
depressive episodes with short-duration
hypomania, 786–789
Internet gaming disorder, 795–798
neurobehavioral disorder associated with
prenatal alcohol exposure, 798–801
nonsuicidal self-injury, 803–805
persistent complex bereavement disorder,
789–792
suicidal behavior disorder, 801–803
Conduct disorder, 32, 461, 469–475
associated features supporting diagnosis of,
472–473
comorbidity with, 475
culture-related diagnostic issues in, 474
development and course of, 473
diagnostic criteria for, 469–471 | dsm5.pdf |
98ad50f7b918-2 | development and course of, 473
diagnostic criteria for, 469–471
diagnostic features of, 472
differential diagnosis of, 474–475
functional consequences of, 474
gender-related diagnostic issues in, 474
prevalence of, 473
risk and prognostic factors for, 473–474
specifiers for, 471–472
subtypes of, 471
Conversion disorder (functional neurological
symptom disorder), 309, 310, 318–321
associated features supporting diagnosis of,
319–320
comorbidity with, 321
culture-related diagnostic issues in, 320
development and course of, 320
diagnostic criteria for, 318–319
diagnostic features of, 319
differential diagnosis of, 321
functional consequences of, 321
gender-related diagnostic issues in, 320
prevalence of, 320
risk and prognostic factors for, 320 | dsm5.pdf |
1013db57e035-0 | Index 923
Creutzfeldt-Jakob disease. See Prion disease,
major or mild neurocognitive disorder due to
Crime or interaction with the legal system,
problems related to, 725
Criterion for clinical significance, 21
Cross-cutting symptom measures, 733–741
DSM-5 Level 1 Cross-Cutting Symptom
Measure, 734–736, 738–741
DSM-5 Level 2 Cross-Cutting Symptom
Measures, 734, 735, 736, 737
frequency of use of, 737
Cultural concepts of distress, 750, 758, 759, 833–837
Cultural explanations or perceived causes, 14, 758
Cultural formulation, 749–759
definitions related to, 749
diagnostic importance of, 758–759
outline for, 749–750
relationship to DSM-5 nosology, 758
Cultural Formulation Interview (CFI), 17, 24, 749,
750–757
domains of assessment, 751
indications for, 751
Informant Version, 755–757
supplementary modules of, 751
Cultural idioms of distress, 14, 758
Cultural issues, 14–15, 749–759
in anxiety disorders
generalized anxiety disorder, 224
panic attacks, 216
panic disorder, 211–212
selective mutism, 196
separation anxiety disorder, 193
social anxiety disorder (social phobia),
205–206
specific phobia, 201
in bipolar and related disorders
bipolar I disorder, 130
bipolar and related disorder due to another
medical condition, 147
in depressive disorders
major depressive disorder, 166 | dsm5.pdf |
1013db57e035-1 | medical condition, 147
in depressive disorders
major depressive disorder, 166
premenstrual dysphoric disorder, 173
in disruptive, impulse-control, and conduct
disorders
conduct disorder, 474
intermittent explosive disorder, 468
oppositional defiant disorder, 465
in dissociative disorders
depersonalization/derealization disorder,
304
dissociative amnesia, 300
dissociative identity disorder, 295
in enuresis, 357
in feeding and eating disorders
anorexia nervosa, 342avoidant/restrictive f ood intake disorder,
336
binge-eating disorder, 352
bulimia nervosa, 348
pica, 331
in fetishistic disorder, 701
in gender dysphoria, 457
in neurocognitive disorders, 609
due to Alzheimer’s disease, 613
in neurodevelopmental disorders
attention-deficit/hyperactivity disorder,
62
autism spectrum disorder, 57
developmental coordination disorder, 76
intellectual disabi lity (intellectual
developmental disorder), 39
specific learning disorder, 72–73
stereotypic movement disorder, 79
tic disorders, 83
in obsessive-compulsive and related disorders
body dysmorphic disorder, 245
hoarding disorder, 250
obsessive-compulsive disorder, 240
trichotillomania (hair-pulling disorder),
253
in personality disorders, 648
antisocial personality disorder, 662
avoidant personality disorder, 674
borderline personality disorder, 665–666
dependent personality disorder, 677
histrionic personality disorder, 668
obsessive-compulsive personality disorder,
681
paranoid personality disorder, 651 | dsm5.pdf |
1013db57e035-2 | 681
paranoid personality disorder, 651
schizoid personality disorder, 654
schizotypal personality disorder, 657
in schizophrenia spectrum and other psychotic
disorders
brief psychotic disorder, 95
delusional disorder, 93
schizoaffective disorder, 108–109
schizophrenia, 103
in sexual dysfunctions, 423
delayed ejaculation, 425
erectile disorder, 428
female orgasmic disorder, 432
female sexual interest/arousal disorder,
435–436
genito-pelvic pain/penetration disorder,
439
male hypoactive sexual desire disorder,
442
premature (early) ejaculation, 445
substance/medication-induced sexual
dysfunction, 449 | dsm5.pdf |
92b822a5e074-0 | 924 Index
Cultural issues (continued)
in sleep-wake disorders
central sleep apnea hypopnea, 381
circadian rhythm sleep-wake disorders,
advanced sleep phase type, 394
narcolepsy, 376
nightmare disorder, 406
substance/medication-induced sleep
disorder, 418
in somatic symptoms and related disorders
conversion disorder (functional
neurological symptom disorder), 320
illness anxiety disorder, 317
psychological factors affecting other
medical conditions, 323
somatic symptom disorder, 313
in substance-related and addictive disorders
alcohol intoxi cation, 498
alcohol use disorder, 495
caffeine withdrawal, 508
cannabis use disorder, 514
gambling disorder, 588
inhalant use disorder, 536
opioid use disorder, 544
other hallucinogen use disorder, 526
other (or unknown) substance use
disorder, 580
other (or unknown) substance withdrawal,
580
phencyclidine use disorder, 522
sedative, hypnotic, or anxiolytic use
disorder, 554
stimulant use disorder, 565
tobacco use disorder, 574
in suicidal behavior disorder, 802
in trauma- and stressor-related disorders
acute stress disorder, 285
adjustment disorders, 288
posttraumatic stress disorder, 278
reactive attachment disorder, 267
Cultural syndromes, 14, 758
Culture-bound syndromes, 14, 758
Cyclothymic disorder, 123, 139–141
comorbidity with, 141
development and course of, 140–141
diagnostic criteria for, 139–140
diagnostic features of, 140 | dsm5.pdf |
92b822a5e074-1 | diagnostic criteria for, 139–140
diagnostic features of, 140
differential diagnosis of, 141
prevalence of, 140
risk and prognostic factors for, 141
Definition of a mental disorder, 20
Delayed ejaculation, 423, 424–426
associated features supporting diagnosis of,
424–425comorbidity with, 426
culture-related diagnostic issues in, 425
development and course of, 425
diagnostic criteria for, 424
diagnostic features of, 424
differential diagnosis of, 425–426
functional consequences of, 425
prevalence of, 425
risk and prognostic factors for, 425
Delirium, 591, 596–602
due to another medical condition, 597
associated features supporting diagnosis of, 600
development and course of, 600–601
diagnostic criteria for, 596–598
diagnostic features of, 599–600
diagnostic markers for, 601
differential diagnosis of, 601
functional consequences of, 601
medication-induced, 597, 599
due to multiple etiologies, 597
other specified, 602
prevalence of, 600
recording procedures for, 598–599
risk and prognostic factors for, 601
specifiers for, 599
substance intoxication, 596–597, 598
substance withdrawal, 597, 598–599
unspecified, 602
Delusional disorder, 89, 90–93
associated features supporting diagnosis of, 92
culture-related diagnostic issues in, 93
delusional symptoms in partner of individual
with, 122
development and course of, 92–93
diagnostic criteria for, 90–91 | dsm5.pdf |
92b822a5e074-2 | development and course of, 92–93
diagnostic criteria for, 90–91
diagnostic features of, 92
functional consequences of, 93
prevalence of, 92
subtypes of, 91–92
Delusions, 87, 89, 90–93
bizarre, 87, 91
of control, 87
erotomanic, 87, 90
grandiose, 87, 90
jealous, 90, 91
mixed type, 91
nihilistic, 87
nonbizarre, 87
persecutory, 87, 90–91
referential, 87
with significant overlapping mood episodes,
122
somatic, 87, 90, 92
unspecified type, 91
Dementia, 591. See also Neurocognitive disorders | dsm5.pdf |
74bcd0b0cf90-0 | Index 925
Dependent personality disorder, 645, 646, 675–678
associated features supporting diagnosis of, 677
culture-related diagnostic issues in, 677
development and course of, 677
diagnostic criteria for, 675
diagnostic features of, 675–677
differential diagnosis of, 677–678
gender-related diagnostic issues in, 677
prevalence of, 677
Depersonalization/derealization disorder, 291,
302–306
associated features supporting diagnosis of, 303
comorbidity with, 306
culture-related diagnostic issues in, 304
development and course of, 303–304
diagnostic criteria for, 302
diagnostic features of, 302–303
differential diagnosis of, 305–306
functional consequences of, 304–305
prevalence of, 303
risk and prognostic factors for, 304
Depressive disorder du e to another medical
condition, 155, 180–183
associated features supporting diagnosis of, 181
comorbidity with, 183
development and course of, 181–182
diagnostic criteria for, 180–181
diagnostic features of, 181
diagnostic markers for, 182
differential diagnosis of, 182–183
functional consequences of, 182
gender-related diagnostic issues in, 182
risk and prognostic factors for, 182
suicide risk in, 182
Depressive disorders, 155–188
depressive disorder due to another medical
condition, 155, 180–183
disruptive mood dysregulation disorder, 155,
156–160
highlights of changes fr om DSM-IV to DSM-5,
810–811
major depressive disorder, 155, 160–168 | dsm5.pdf |
74bcd0b0cf90-1 | 810–811
major depressive disorder, 155, 160–168
other specified depres sive disorder, 155,
183–184
persistent depressive disorder (dysthymia),
155, 168–171
premenstrual dysphoric disorder, 155, 171–175
specifiers for, 184–188
substance/medication-induced depressive
disorder, 155, 175–180
unspecified depressive disorder, 155, 184
Depressive episode or symptoms in bipolar and
related disorders
bipolar I disorder, 125–126, 129
bipolar II disorder, 133–134, 135–136cyclothymic disorder, 139, 140
other specified bipolar and related disorder,
148
Depressive episodes with short-duration
hypomania, 786–789
associated features supporting diagnosis of,
788
comorbidity with, 789
diagnostic features of, 788
differential diagnosis of, 788–789
functional consequences of, 788
prevalence of, 788
proposed criteria for, 786–787
risk and prognostic factors for, 788
suicide risk in, 788
Developmental coordination disorder, 32, 74–77
associated features supporting diagnosis of, 75
comorbidity with, 76
culture-related diagnostic issues in, 76
development and course of, 75–76
diagnostic criteria for, 74
diagnostic features of, 74–75
differential diagnosis of, 76–77
functional consequences of, 76
prevalence of, 75
risk and prognostic factors for, 76
Dhat syndrome, 833–834
Diagnosis, 5–6
assessment and monitoring measures for, | dsm5.pdf |
74bcd0b0cf90-2 | Diagnosis, 5–6
assessment and monitoring measures for,
23–24, 733–748
categorical, 5, 8, 12, 13, 19, 20
clinical utility of, 20
coding and reporting procedures for, 12, 16,
22, 23, 29
criterion for clinical significance, 21
culture and, 14–15, 749–759
definition of a mental disorder, 20
diagnostic criteria and descriptors, 21
dimensional approach to, 5, 8, 9, 12–13, 17
elements of, 21–24
in forensic settings, 25
of medication-induced movement disorders,
20, 22, 29, 709–714
of other conditions that may be a focus of
clinical attention, 20, 22, 29, 715–727
principal, 22–23
provisional, 23
Diagnostic criteria, 21, 29
case formulation and, 19
proposed criteria for conditions for further
study, 11, 783
revisions of, 6–10
subtypes and specifiers for, 21–22
validators for, 5, 9, 11, 12, 20
Diagnostic spectra, 6, 9, 12 | dsm5.pdf |
08b8c6b8b78e-0 | 926 Index
Disinhibited social engagement disorder, 265,
268–270
associated features supporting diagnosis of,
269
development and course of, 269–270
diagnostic criteria for, 268–269
diagnostic features of, 269
differential diagnosis of, 270
functional consequences of, 270
prevalence of, 269
risk and prognostic factors for, 270
Disorganized thinking (speech), 88
Disruptive, impulse-control, and conduct
disorders, 461–480
antisocial personality disorder, 461, 476, 645,
646, 659–663
conduct disorder, 461, 469–475
highlights of changes fr om DSM-IV to DSM-5,
815
intermittent explosive disorder, 461, 466–469
kleptomania, 461, 478–479
oppositional defiant disorder, 461, 462–466
other specified disrupti ve, impulse-control,
and conduct disorder, 461, 479
pyromania, 461, 476–477
unspecified disruptive, impulse-control, and
conduct disorder, 480
Disruptive mood dysregulation disorder, 155,
156–160
comorbidity with, 160
development and course of, 157
diagnostic criteria for, 156
diagnostic features of, 156–157
differential diagnosis of, 158–160
functional consequences of, 158
gender-related diagnostic issues in, 158
prevalence of, 157
risk and prognostic factors for, 157–158
suicide risk in, 158
Dissociative amnesia, 291, 298–302
associated features supporting diagnosis of, 299
comorbidity with, 302 | dsm5.pdf |
08b8c6b8b78e-1 | associated features supporting diagnosis of, 299
comorbidity with, 302
culture-related diagnostic issues in, 300
development and course of, 299
diagnostic criteria for, 298
diagnostic features of, 298–299
differential diagnosis of, 300–302
functional consequences of, 300
prevalence of, 299
risk and prognostic factors for, 299–300
suicide risk in, 300
Dissociative disorders, 291–307
depersonalization/derealization disorder, 291,
302–306
dissociative amnesia, 291, 298–302dissociative identity disorder, 291–298
highlights of changes fr om DSM-IV to DSM-5,
812
other specified dissoc iative disorder, 292,
306–307
unspecified dissociative disorder, 307
Dissociative identity disorder, 291–298
associated features supporting diagnosis of,
294
comorbidity with, 297–298
culture-related diagnostic issues in, 295
development and course of, 294
diagnostic criteria for, 292
diagnostic features of, 292–294
differential diagnosis of, 296–297
functional consequences of, 295–296
gender-related diagnostic issues in, 295
prevalence of, 294
risk and prognostic factors for, 294–295
suicide risk in, 295
Dissociative reactions to stressful events, acute,
306–307
Dissociative stupor or coma, 292
Dissociative trance, 292, 307
Down syndrome, 38, 40, 44, 53
DSM, history of, 5, 6
DSM-5 | dsm5.pdf |
08b8c6b8b78e-2 | DSM, history of, 5, 6
DSM-5
cultural issues in, 14–15, 749–759
developmental and lifespan considerations in,
13
forensic use of, 25
gender differences in, 15
glossary of technical terms in, 817–831
harmonization with ICD-11, 11–12
highlights of changes from DSM-IV to, 809–817
anxiety disorders, 811
bipolar and related disorders, 810
depressive disorders, 810–811
disruptive, impulse-control, and conduct
disorders, 815
dissociative disorders, 812
elimination disorders, 813
feeding and eating disorders, 813
gender dysphoria, 814–815
neurodevelopmental disorders, 809–810
obsessive-compulsive and related
disorders, 811–812
paraphilic disorders, 816
personality disorders, 816
schizophrenia spectrum and other
psychotic disorders, 810
sexual dysfunctions, 814
sleep-wake disorders, 814
somatic symptom and related disorders,
812–813 | dsm5.pdf |
e6a796502e70-0 | Index 927
substance-related and addictive disorders,
815–816
trauma- and stressor-related disorders, 812
multiaxial system and, 16
online enhancements of, 17
organizational structure of, 10–11, 13
other specified and unspecified mental
disorders in, 15–16, 19–20, 707–708
revision process for, 5, 6–10
expert review, 8–10
field trials, 7–8
proposals for revisions, 7
public and professional review, 8
use of, 19–24
assessment and monitoring tools, 23–24,
733–748
case formulation, 19–20
coding and reporting procedures, 12, 16,
22, 23, 29
definition of a mental disorder, 20–21
elements of a diagnosis, 21–24
DSM-5 Level 1 Cross-Cutting Symptom Measure,
734–736
adult self-rated version, 734, 735, 738–739
parent/guardian-rated version, 734, 736,
740–741
scoring and interpretation of, 734–736
DSM-5 Level 2 Cross-Cutting Symptom
Measures, 734, 735, 736, 737
Dysthymia. See Persistent depressive disorder
(dysthymia)
Dystonia, medication-induced, 22
acute, 711
tardive, 712
Eating disorders. See Feeding and eating disorders
Economic problems, 724
Educational problems, 723
Ejaculation
delayed, 423, 424–426
premature (early), 423, 443–446 | dsm5.pdf |
e6a796502e70-1 | premature (early), 423, 443–446
Elements of diagnosis, 21–24
Elimination disorders, 355–360
encopresis, 355, 357–359
enuresis, 355–357
highlights of changes fr om DSM-IV to DSM-5,
813
other specified elimin ation disorder, 359
unspecified elimination disorder, 360
Encopresis, 355, 357–359
associated features supporting diagnosis of, 358
comorbidity with, 359
development and course of, 359
diagnostic criteria for, 357–358
diagnostic features of, 358diagnostic markers for, 359
differential diagnosis of, 359
prevalence of, 359
risk and prognostic factors for, 359
subtypes of, 358
Enuresis, 355–357
associated features supporting diagnosis of, 356
comorbidity with, 356
culture-related diagnostic issues in, 356
development and course of, 356
diagnostic criteria for, 355
diagnostic features of, 355–356
differential diagnosis of, 356
functional consequences of, 356
gender-related diagnostic issues in, 356
prevalence of, 356
risk and prognostic factors for, 356
subtypes of, 355
Erectile disorder, 423, 426–429
associated features supporting diagnosis of, 427
comorbidity with, 429
culture-related diagnostic issues in, 428
development and course of, 427–428
diagnostic criteria for, 426–427
diagnostic features of, 427
diagnostic markers for, 428
differential diagnosis of, 428–429
functional consequences of, 428
prevalence of, 427 | dsm5.pdf |
e6a796502e70-2 | functional consequences of, 428
prevalence of, 427
risk and prognostic factors for, 428
Excoriation (skin-picking) disorder, 235, 236,
254–257
associated features supporting diagnosis of, 255
comorbidity with, 257
development and course of, 255
diagnostic criteria for, 254
diagnostic features of, 254–255
diagnostic markers for, 255
differential diagnosis of, 256
functional consequences of, 256
prevalence of, 255
risk and prognostic factors for, 255
Exhibitionistic disorder, 685, 689–691
comorbidity with, 691
development and course of, 690
diagnostic criteria for, 689
diagnostic features of, 689–690
differential diagnosis of, 691
functional consequences of, 691
gender-related diagnostic issues in, 691
prevalence of, 690
risk and prognostic factors for, 690–691
specifiers for, 689
subtypes of, 689
Externalizing disorders, 13 | dsm5.pdf |
9ff3be3577f3-0 | 928 Index
Factitious disorder, 309, 310, 324–326
associated features supporting diagnosis of,
325–326
development and course of, 326
diagnostic criteria for, 324–325
diagnostic features of, 325
differential diagnosis of, 326
imposed on another, 310, 325–325, 338
prevalence of, 326
recording procedures for, 325
Family upbringing, problems related to, 715–716
Feeding and eating disorders, 329–354
anorexia nervosa, 329, 338–345
avoidant/restrictive food intake disorder, 329,
334–338
binge-eating disorder, 329, 350–353
bulimia nervosa, 329, 345–350
highlights of changes fr om DSM-IV to DSM-5,
813
other specified feeding or eating disorder,
353–354
pica, 329–331
rumination disorder, 329, 332–333
unspecified feeding or eating disorder, 354
Female orgasmic disorder, 423, 429–432
associated features supporting diagnosis of,
430–431
comorbidity with, 432
culture-related diagnostic issues in, 432
development and course of, 431
diagnostic criteria for, 429–430
diagnostic features of, 430
diagnostic markers for, 432
differential diagnosis of, 432
functional consequences of, 432
prevalence of, 431
risk and prognostic factors for, 431–432
Female sexual interest/arousal disorder, 423,
433–437
associated features supporting diagnosis of,
434–435
comorbidity with, 436–437 | dsm5.pdf |
9ff3be3577f3-1 | 434–435
comorbidity with, 436–437
culture-related diagnostic issues in, 435–436
development and course of, 435
diagnostic criteria for, 433
diagnostic features of, 433–434
differential diagnosis of, 436
functional consequences of, 436
gender-related diagnostic issues in, 436
prevalence of, 435
risk and prognostic factors for, 435
Fetishistic disorder, 685, 700–702
associated features supporting diagnosis of, 701
comorbidity with, 702
culture-related diagnostic issues in, 701development and course of, 701
diagnostic criteria for, 700
diagnostic features of, 701
differential diagnosis of, 702
functional consequences of, 701–702
gender-related diagnostic issues in, 701
specifiers for, 701
Forensic settings, 25
Formal thought disorder, 88
Frontotemporal neurocognitive disorder, major or
mild, 591, 603, 614–618
associated features supporting diagnosis of,
616
development and course of, 616
diagnostic criteria for, 614–615
diagnostic features of, 615–616
diagnostic markers for, 616–617
differential diagnosis of, 617–618
functional consequences of, 617
prevalence of, 616
risk and prognostic factors for, 616
Frotteuristic disorder, 685, 691–694
comorbidity with, 693–694
development and course of, 693
diagnostic criteria for, 691–692
diagnostic features of, 692
differential diagnosis of, 693
gender-related diagnostic issues in, 693
prevalence of, 692–693 | dsm5.pdf |
9ff3be3577f3-2 | gender-related diagnostic issues in, 693
prevalence of, 692–693
risk and prognostic factors for, 693
specifiers for, 692
Functional neurological symptom disorder. See
Conversion disorder
GAF (Global Assessment of Functioning) scale, 16
Gambling disorder, 481, 585–589
associated features supporting diagnosis of,
587
comorbidity with, 589
culture-related diagnostic issues in, 588
development and course of, 587–588
diagnostic criteria for, 585–586
diagnostic features of, 586–587
differential diagnosis of, 589
functional consequences of, 589
gender-related diagnostic issues in, 588
prevalence of, 587
risk and prognostic factors for, 588
specifiers for, 586
Gender differences, 15
Gender dysphoria, 451–459
associated features supporting diagnosis of,
454
comorbidity with, 458–459
culture-related diagnostic issues in, 457 | dsm5.pdf |
1829eef1b479-0 | Index 929
development and course of, 454–456
in association with a disorder of sex
development, 456
without a disorder of sex development,
455–456
diagnostic criteria for, 452–453
diagnostic features of, 453–454
diagnostic markers for, 457
differential diagnosis of, 458
functional consequences of, 457–458
highlights of changes fr om DSM-IV to DSM-5,
814–815
other specified, 459
prevalence of, 454
risk and prognostic factors for, 456–457
specifiers for, 453
unspecified, 459
Generalized anxiety disorder, 190, 222–226
associated features supporting diagnosis of, 223
comorbidity with, 226
culture-related diagnostic issues in, 224
development and course of, 223–224
diagnostic criteria for, 222
diagnostic features of, 222–223
differential diagnosis of, 225–226
functional consequences of, 225
gender-related diagnostic issues in, 224–225
prevalence of, 223
risk and prognostic factors for, 224
Genito-pelvic pain/penetration disorder, 423,
437–440
associated features supporting diagnosis of,
438
comorbidity with, 440
culture-related diagnostic issues in, 439
development and course of, 439
diagnostic criteria for, 437
diagnostic features of, 437–438
differential diagnosis of, 440
functional consequences of, 439
gender-related diagnostic issues in, 439
prevalence of, 438
risk and prognostic factors for, 439
Global Assessment of Functioning (GAF) scale, 16
Global developmental delay, 31, 41 | dsm5.pdf |
1829eef1b479-1 | Global developmental delay, 31, 41
Glossary of technical terms, 817–831
Hair pulling. See Trichotillomania (hair-pulling
disorder)
Hallucinations, 87–88
auditory, 87, 103, 116, 122
gustatory, 116
hypnagogic, 87
hypnopompic, 88
olfactory, 116, 118tactile, 116
visual, 102, 103, 104, 116, 118
Hallucinogen persisting perception disorder,
531–532
associated features supporting diagnosis of, 531
comorbidity with, 532
development and course of, 532
diagnostic criteria for, 531
diagnostic features of, 531
differential diagnosis of, 532
functional consequences of, 532
prevalence of, 531
risk and prognostic factors for, 532
Hallucinogen-related disorders, 481, 520–533
diagnoses associated with, 482
hallucinogen persisting perception disorder,
531–532
other hallucinogen-induced disorders,
532–533
other hallucinogen intoxication, 529–530
other hallucinogen use disorder, 523–527
other phencyclidine-induced disorders, 532
phencyclidine intoxication, 527–529
phencyclidine use disorder, 520–523
unspecified hallucinogen-related disorder, 533
unspecified phencyclidine-related disorder, 533
Histrionic personality disorder, 645, 646, 667–669
associated features supporting diagnosis of,
668
culture-related diagnostic issues in, 668
diagnostic criteria for, 667
diagnostic features of, 667–668 | dsm5.pdf |
1829eef1b479-2 | diagnostic criteria for, 667
diagnostic features of, 667–668
differential diagnosis of, 669
gender-related diagnostic issues in, 668
prevalence of, 668
HIV infection, major or mild neurocognitive
disorder due to, 591, 604, 632–634
associated features supporting diagnosis of, 633
comorbidity with, 634
development and course of, 633
diagnostic criteria for, 632
diagnostic features of, 632
diagnostic markers for, 634
differential diagnosis of, 634
functional consequences of, 634
prevalence of, 633
risk and prognostic factors for, 633
Hoarding disorder, 235, 236, 247–251
associated features supporting diagnosis of, 249
comorbidity with, 251
culture-related diagnostic issues in, 250
development and course of, 249
diagnostic criteria for, 247
diagnostic features of, 248–249
differential diagnosis of, 250–251 | dsm5.pdf |
37cf93612bec-0 | 930 Index
Hoarding disorder (continued)
functional consequences of, 250
gender-related diagnostic issues in, 250
prevalence of, 249
risk and prognostic factors for, 249
specifiers for, 248
Housing problems, 723–724
Huntington’s disease, 81, 117, 181, 182
major or mild neurocognitive disorder due to,
591, 604, 638–641
associated features supporting diagnosis
of, 639
development and course of, 639–640
diagnostic criteria for, 638–639
diagnostic features of, 639
diagnostic markers for, 640
differential diagnosis of, 640–641
functional consequences of, 640
prevalence of, 639
risk and prognostic factors for, 640
Hypersomnolence disorder, 361, 368–372
associated features supporting diagnosis of,
370
comorbidity with, 372
development and course of, 370
diagnostic criteria for, 368–369
diagnostic features of, 369–370
diagnostic markers for, 371
differential diagnosis of, 371–372
functional consequences of, 371
other specified, 421
prevalence of, 370
relationship to International Classification of
Sleep Disorders, 372
risk and prognostic factors for, 370–371
unspecified, 421
Hypochondriasis, 310, 315–316, 318. See also
Illness anxiety disorder
Hypomanic episode or symptoms in bipolar and
related disorders
bipolar I disorder, 124–125, 129
bipolar II disorder, 132–133, 135–136
bipolar and related disorder due to another | dsm5.pdf |
37cf93612bec-1 | bipolar and related disorder due to another
medical condition, 146
cyclothymic disorder, 139, 140
depressive episodes with short-duration
hypomania, 786–789
other specified bipolar and related disorder,
148
ICD. See International Classification of Diseases
ICF (International Classification of Functioning,
Disability and Health), 21, 734
ICSD-2. See International Classification of Sleep
Disorders, 2nd EditionIdentity disturbance due to prolonged and intense
coercive persuasion, 306
Illness anxiety disorder, 309, 310, 315–318
associated features supporting diagnosis of, 316
brief, 327
comorbidity with, 318
culture-related diagnostic issues in, 317
diagnostic criteria for, 315
diagnostic features of, 315–316
differential diagnosis of, 317–318
functional consequences of, 317
prevalence of, 316
risk and prognostic factors for, 316–317
without excessive health-related behaviors,
327
Inhalant intoxication, 538–540
associated features supporting diagnosis of,
539
diagnostic criteria for, 538
diagnostic features of, 538
differential diagnosis of, 539–540
functional consequences of, 539
gender-related diagnostic issues in, 539
prevalence of, 539
Inhalant-related disorders, 481, 533–540
diagnoses associated with, 482
inhalant intoxication, 538–540
inhalant use disorder, 533–538
other inhalant-induced disorders, 540
unspecified inhalant-related disorder, 540
Inhalant use disorder, 533–538
associated features supporting diagnosis of,
535 | dsm5.pdf |
37cf93612bec-2 | associated features supporting diagnosis of,
535
comorbidity with, 538
culture-related diagnostic issues in, 536
development and course of, 536
diagnostic criteria for, 533–534
diagnostic features of, 535
diagnostic markers for, 536–537
differential diagnosis of, 537
functional consequences of, 537
gender-related diagnostic issues in, 536
prevalence of, 535–536
risk and prognostic factors for, 536
specifiers for, 535
Insomnia disorder, 361, 362–368
associated features supporting diagnosis of,
364
brief, 420
comorbid ity w ith, 368
development and course of, 365
diagnostic criteria for, 362–363
diagnostic features of, 363–364
diagnostic markers for, 366–367
differential diagnosis of, 367–368 | dsm5.pdf |
f365361d917d-0 | Index 931
functional consequences of, 367
gender-related diagnostic issues in, 366
other specified, 420
prevalence of, 364–365
relationship to International Classification of
Sleep Disorders, 368
restricted to nonrestorative sleep, 420
risk and protective factors for, 366
unspecified, 420–421
Intellectual disability (intellectual developmental
disorder), 31, 33–41
associated features supporting diagnosis of, 38
coding and reporting for, 33
comorbidity with, 40
culture-related diagnostic issues in, 39
development and course of, 38–39
diagnostic criteria for, 33
diagnostic features of, 37–38
diagnostic markers for, 39
differential diagnosis of, 39–40
gender-related diagnostic issues in, 39
global developmental delay, 31, 41
prevalence of, 38
relationship to other classifications, 40–41
risk and prognostic factors for, 39
specifiers for levels of severity of, 33, 34–36
unspecified intellectual disability, 41
Intermittent explosive disorder, 461, 466–469
associated features supporting diagnosis of,
467
comorbidity with, 469
culture-related diagnostic issues in, 468
development and course of, 467
diagnostic criteria for, 466
diagnostic features of, 466–467
differential diagnosis of, 468–469
functional consequences of, 468
gender-related diagnostic issues in, 468
prevalence of, 467
risk and prognostic factors for, 467–468
Internalizing disorders, 13
International Classification of Diseases (ICD), 21
revision process for ICD-11, 6, 10, 11–12 | dsm5.pdf |
f365361d917d-1 | revision process for ICD-11, 6, 10, 11–12
use of ICD-9-CM and ICD-10 codes, 12, 16, 22,
23, 29
International Classification of Functioning,
Disability and Health (ICF), 21, 734
International Classification of Sleep Disorders, 2nd
Edition (ICSD-2), relationship of DSM-5 to,
361–362
circadian rhythm sleep-wake disorders, 398
hypersomnolence disorder, 372
insomnia disorder, 368
narcolepsy, 378
nightmare disorder, 407obstructive sleep ap nea hypopnea, 383
rapid eye movement sleep behavior disorder,
410
restless legs syndrome, 413
sleep-related hypoventilation, 390
substance/medication-induced sleep disorder,
420
Internet gaming disorder, 795–798
associated features supporting diagnosis of,
797
comorbidity with, 798
diagnostic features of, 796–797
differential diagnosis of, 797–798
functional consequences of, 797
prevalence of, 797
proposed criteria for, 795–796
risk and prognostic factors for, 797
subtypes of, 796
Intoxication, 481, 485–487
alcohol, 497–499
associated with use of multiple substances, 486
caffeine, 503–506
cannabis, 516–517
delirium due to, 598
development and course of, 487
duration of effects and, 486
inhalant, 538–540
laboratory findings associated with, 486–487
opioid, 546–547 | dsm5.pdf |
f365361d917d-2 | laboratory findings associated with, 486–487
opioid, 546–547
other hallucinogen, 529–530
other (or unknown) substance, 581–582
phencyclidine, 527–529
recording procedures for, 487
related to route of administration and speed of
substance effects, 486
sedative, hypnotic, or anxiolytic, 556–557
stimulant, 567–569
Jealousy, obsessional, 264
Jikoshu-kyofu, 264
Khyâl cap, 211, 212, 233, 834
Kleptomania, 461, 478–479
associated features supporting diagnosis of,
478
comorbidity with, 478
development and course of, 478
diagnostic criteria for, 478
diagnostic features of, 478
differential diagnosis of, 478
functional consequences of, 478
prevalence of, 478
risk and prognostic factors for, 478
Koro, 264
Kufungisisa, 14, 834–835 | dsm5.pdf |
4292add49d37-0 | 932 Index
Language disorder, 31, 42–44
associated features supporting diagnosis of, 43
comorbidity with, 44
development and course of, 43
diagnostic criteria for, 42
diagnostic features of, 42
differential diagnosis of, 43
risk and prognostic factors for, 43
Learning disorder. See Specific learning disorder
Level of Personality Fu nctioning Scale (LPFS),
772, 775–778
Lewy bodies, major or mild neurocognitive
disorder with, 591, 603, 618–621
associated features supporting diagnosis of, 619
comorbidity with, 621
development and course of, 619–620
diagnostic criteria for, 618–619
diagnostic features of, 619
diagnostic markers for, 620
differential diagnosis of, 620
functional consequences of, 620
prevalence of, 619
risk and prognostic factors for, 620
LPFS (Level of Personality Functioning Scale),
772, 775–778
Major depressive disorder, 155, 160–168
associated features supporting diagnosis of,
164–165
comorbidity with, 168
culture-related diagnostic issues in, 166
development and course of, 165–166
diagnostic criteria for, 160–162
diagnostic features of, 162–164
differential diagnosis of, 167–168
functional consequences of, 167
gender-related diagnostic issues in, 167
prevalence of, 165
risk and prognostic factors for, 166
suicide risk in, 164, 167
Major depressive episode in bipolar and related
disorders
bipolar I disorder, 125–126, 129 | dsm5.pdf |
4292add49d37-1 | disorders
bipolar I disorder, 125–126, 129
bipolar II disorder, 133–134, 135–136
other specified bipolar and related disorder,
148
Maladi moun, 14, 835
Male hypoactive sexual desire disorder, 423,
440–443
associated features supporting diagnosis of,
441–442
comorbidity with, 443
culture-related diagnostic issues in, 442
development and course of, 442
diagnostic criteria for, 440–441diagnostic features of, 441
differential diagnosis of, 443
gender-related diagnostic issues in, 442–443
prevalence of, 442
risk and prognostic factors for, 442
Manic episode
in bipolar I disorder, 124, 127–129
in bipolar and related disorder due to another
medical cond ition, 146
Medication-induced delirium, 597, 599
Medication-induced movement disorders and
other adverse effects of medication, 20, 22,
29, 709–714
antidepressant discontinuation syndrome, 22,
712–714
medication-induced acute akathisia, 22, 711
medication-induced acute dystonia, 711
medication-induced postural tremor, 712
neuroleptic-induced parkinsonism, 709
neuroleptic malignant syndrome, 22, 709–711
other adverse effect of medication, 712–714
other medication-induced movement
disorder, 712
other medication-induced parkinsonism, 709
tardive akathisia, 712
tardive dyskinesia, 22, 712
tardive dystonia, 712
Mental disorder(s) | dsm5.pdf |
4292add49d37-2 | tardive dystonia, 712
Mental disorder(s)
culture and, 14–15, 749–759
definition of, 20
criterion for clinical significance, 21
in forensic settings, 25
gender and, 15
Motor disorders, neurodevelopmental, 32, 74–85
developmental coordination disorder, 74–77
stereotypic movement disorder, 77–80
tic disorders, 81–85
Movement disorders, medication-induced. See
Medication-induced movement disorders
and other adverse effects of medication
Muscle dysmorphia, 236, 243, 245
Narcissistic personality disorder, 645, 646,
669–672
associated features supporting diagnosis of,
671
development and course of, 671
diagnostic criteria for, 669–670
diagnostic features of, 670–671
differential diagnosis of, 671–672
features and criteria in alternative DSM-5
model for personality disorders, 763,
767–768
gender-related diagnostic issues in, 671
prevalence of, 671 | dsm5.pdf |
077aa1dbf48f-0 | Index 933
Narcolepsy, 361, 372–378
associated features supporting diagnosis of,
374–375
comorbidity with, 377–378
culture-related diagnostic issues in, 376
development and course of, 375
diagnostic criteria for, 372–373
diagnostic features of, 374
diagnostic markers for, 376
differential diagnosis of, 376–377
functional consequences of, 376
prevalence of, 375
relationship to International Classification of
Sleep Disorders, 378
risk and prognostic factors for, 375–376
subtypes of, 373–374
NCDs. See Neurocognitive disorders
Neglect
child, 718–719
spouse or partner, 721
Nervios, 835
Neurobehavioral disorder associated with
prenatal alcohol exposure, 798–801
associated features supporting diagnosis of, 799
comorbidity with, 800–801
development and course of, 800
diagnostic features of, 799
differential diagnosis of, 800
functional consequences of, 800
prevalence of, 800
proposed criteria for, 798–799
suicide risk in, 800
Neurocognitive disorders (NCDs), 591–643
delirium, 591, 596–602
other specified delirium, 602
unspecified delirium, 602
highlights of changes fr om DSM-IV to DSM-5,
816
major and mild neurocognitive disorders, 591,
602–611, 611–643
associated features supporting diagnosis
of, 608
comorbidity with, 610–611
culture-related diagnostic issues in, 609
development and course of, 608–609 | dsm5.pdf |
077aa1dbf48f-1 | culture-related diagnostic issues in, 609
development and course of, 608–609
diagnostic criteria for, 602–606
diagnostic features of, 607–608
diagnostic markers for, 609–610
differential diagnosis of, 610
functional consequences of, 610
gender-related diagnostic issues in, 609
prevalence of, 608
risk and prognostic factors for, 609
specifiers for, 606–607
subtypes of, 591, 603–604, 606, 611–643major or mild frontotemporal neuro-
cognitive disorder, 591, 603, 614–618
major or mild neurocognitive disorder
due to Alzheimer’s disease, 591, 603,
611–614
major or mild neurocognitive disorder
due to another medical condition,
591, 604, 641–642
major or mild neurocognitive disorder
due to HIV infection, 591, 604, 632–
634
major or mild neurocognitive disorder
due to Huntington’s disease, 591,
604, 638–641
major or mild neurocognitive disorder
with Lewy bodies, 591, 603, 618–621
major or mild neurocognitive disorder
due to multiple etiologies, 591, 604,
642–643
major or mild neurocognitive disorder
due to Parkinson’s disease, 591, 604,
636–638
major or mild neurocognitive disorder
due to prion disease, 591, 604, 634–
636
major or mild neurocognitive disorder
due to traumatic brain injury, 591,
603, 624–627, 626
major or mild substance/medication- | dsm5.pdf |
077aa1dbf48f-2 | 603, 624–627, 626
major or mild substance/medication-
induced neurocognitive disorder,
591, 603, 627–632
unspecified neurocognitive disorder,
591, 604, 643
vascular neurocogniti ve disorder, 591,
603, 621–624
neurocognitive domains, 592, 593–595
Neurodevelopmental disorders, 11, 13, 31–86
attention-deficit/hyperactivity disorder, 11,
32, 59–66
autism spectrum disorders, 31–32, 50–59
communication disorders, 31, 41–49
highlights of changes fr om DSM-IV to DSM-5,
809–810
intellectual disabilities, 31, 33–41
motor disorders, 32, 74–85
other specified neurodevelopmental disorder,
86
specific learning disorder, 32, 66–74
specifiers for, 32–33
tic disorders, 32, 81–85
unspecified neurodevelopmental disorder, 86
Neurodevelopmental motor disorders, 32, 74–85
developmental coordination disorder, 74–77
stereotypic movement disorder, 77–80
tic disorders, 81–85 | dsm5.pdf |
5ece3f32df98-0 | 934 Index
Neuroleptic-induced parkinsonism, 709
Neuroleptic malignant syndrome, 22, 709–711
development and course of, 710
diagnostic features of, 710
differential diagnosis of, 711
risk and prognostic factors for, 711
Night eating syndrome, 354
Nightmare disorder, 361, 404–407
associated features supporting diagnosis of, 405
comorbidity with, 407
culture-related diagnostic issues in, 406
development and course of, 405
diagnostic criteria for, 404
diagnostic features of, 404–405
diagnostic markers for, 406
differential diagnosis of, 406–407
functional consequences of, 406
gender-related diagnostic issues in, 406
prevalence of, 405
relationship to International Classification of
Sleep Disorders, 407
risk and prognostic factors for, 405
Nonadherence to medical treatment, 22, 726–727
Non–rapid eye movement sleep arousal
disorders, 361, 399–404
associated features supporting diagnosis of,
400–401
comorbidity with, 403
development and course of, 401
diagnostic criteria for, 399
diagnostic features of, 400
diagnostic markers for, 402
differential diagnosis of, 402–403
functional consequences of, 402
gender-related diagnostic issues in, 401
prevalence of, 401
relationship to International Classification of
Sleep Disorders, 404
risk and prognostic factors for, 401
Nonsuicidal self-injury, 803–805
development and course of, 804
diagnostic features of, 804
differential diagnosis of, 805–806
functional consequences of, 805 | dsm5.pdf |
5ece3f32df98-1 | differential diagnosis of, 805–806
functional consequences of, 805
proposed criteria for, 803
risk and prognostic factors for, 804
Obesity, 22
feeding and eating disorders and, 329, 344,
348, 351–353
sleep-wake disorders and, 413
hypersomnia, 372, 373, 375, 376, 377
obstructive sleep apnea hypopnea,
379–380, 382
sleep-related hypoventilation, 387–388, 389Obsessional jealousy, 264
Obsessive-compulsive disorder (OCD), 235–236,
237–242
associated features supporting diagnosis of,
238–239
comorbidity with, 243
culture-related diagnostic issues in, 240
development and course of, 239
diagnostic criteria for, 237
diagnostic features of, 238
differential diagnosis of, 242–243
functional consequences of, 241–242
gender-related diagnostic issues in, 239, 240
prevalence of, 239
risk and prognostic factors for, 239–240
specifiers for, 236, 238
suicide risk in, 240
Obsessive-compulsive personality disorder, 645,
646, 678–682
associated features supporting diagnosis of,
680–681
culture-related diagnostic issues in, 681
diagnostic criteria for, 678–679
diagnostic features of, 679–680
differential diagnosis of, 681–682
features and criteria in alternative DSM-5
model for personality disorders, 764,
768–769
gender-related diagnostic issues in, 681
prevalence of, 681
Obsessive-compulsive and related disorder due to | dsm5.pdf |
5ece3f32df98-2 | prevalence of, 681
Obsessive-compulsive and related disorder due to
another medical condition, 235, 236, 260–263
associated features supporting diagnosis of,
262
development and course of, 262
diagnostic criteria for, 260–261
diagnostic features of, 261–262
diagnostic markers for, 262
differential diagnosis of, 262–263
Obsessive-compulsive and related disorders,
235–264
body dysmorphic disorder, 235, 236, 242–247
excoriation (skin-picking) disorder, 235, 236,
254–257
highlights of changes fr om DSM-IV to DSM-5,
811–812
hoarding disorder, 235, 236, 247–251
obsessions and compulsions in, 235–236, 239
obsessive-compulsive disorder, 235–236,
237–242
obsessive-compulsive and related disorder
due to another medical condition,
235.236, 260–263
other specified obsess ive-compulsive and
related disorder, 235, 236, 263–264 | dsm5.pdf |
7dae11871449-0 | Index 935
substance/medication-induced obsessive-
compulsive and related disorder, 235,
236, 257–260
trichotillomania (hair-pulling disorder), 235,
236, 251–254
unspecified obsessive-compulsive and related
disorder, 235, 236
Obstructive sleep apnea hypopnea, 378–383
associated features supporting diagnosis of,
379
comorbidity with, 383
culture-related diagnostic issues in, 381
development and course of, 379–380
diagnostic criteria for, 378
diagnostic features of, 379
diagnostic markers for, 381
differential diagnosis of, 381–383
functional consequences of, 381
gender-related diagnostic issues in, 381
prevalence of, 379
relationship to International Classification of
Sleep Disorders, 383
risk and prognostic factors for, 380–381
specifiers for, 378–379
Occupational problems, 723
OCD. See Obsessive-compulsive disorder
Olfactory reference syndrome, 246, 264, 837
Online enhancements, 17
Opioid intoxication, 546–547
diagnostic criteria for, 546–547
diagnostic features of, 547
differential diagnosis of, 547
specifiers for, 547
Opioid-related disorders, 481, 540–550
diagnoses associated with, 482
opioid intoxication, 546–547
opioid use disorder, 541–546
opioid withdrawal, 484, 547–549
other opioid-induced disorders, 549
unspecified opioid-related disorder, 550
Opioid use disorder, 541–546
associated features supporting diagnosis of, 543
comorbidity with, 546 | dsm5.pdf |
7dae11871449-1 | associated features supporting diagnosis of, 543
comorbidity with, 546
culture-related diagnostic issues in, 544
development and course of, 543
diagnostic criteria for, 541–542
diagnostic features of, 542
diagnostic markers for, 544
differential diagnosis of, 545–546
functional consequences of, 544–545
gender-related diagnostic issues in, 544
prevalence of, 543
risk and prognostic factors for, 543–544
specifiers for, 542
suicide risk in, 544Opioid withdrawal, 484, 547–549
associated features supporting diagnosis of, 549
development and course of, 549
diagnostic criteria for, 547–548
diagnostic features of, 548
differential diagnosis of, 549
prevalence of, 549
Oppositional defiant disorder, 32, 461, 462–466
associated features supporting diagnosis of,
464
comorbidity with, 466
culture-related diagnostic issues in, 465
development and course of, 464
diagnostic criteria for, 462–463
diagnostic features of, 463
differential diagnosis of, 465
functional consequences of, 465
prevalence of, 464
risk and prognostic factors for, 464
specifiers for, 463
Other circumstances of personal history, 726
Other conditions that may be a focus of clinical
attention, 20, 22, 29, 715–727
abuse and neglect, 717–722
adult maltreatment and neglect problems,
720–722
child maltreatment and neglect problems,
717–719
educational and occupational problems, 723
housing and economic problems, 723–724 | dsm5.pdf |
7dae11871449-2 | educational and occupational problems, 723
housing and economic problems, 723–724
nonadherence to medical treatment, 726–727
other circumstances of personal history, 726
other health service encounters for counseling
and medical advice, 725
other problems related to the social
environment, 724–725
problems related to access to medical and
other health care, 726
problems related to crime or interaction with
the legal system, 725
problems related to other psychosocial,
personal, and environmental
circumstances, 725
relational problems, 715–717
other problems relate d to primary support
group, 716–717
problems related to family upbringing,
715–716
Other hallucinogen intoxication, 529–530
diagnostic criteria for, 529
diagnostic features of, 529
differential diagnosis of, 530
functional consequences of, 530
prevalence of, 530
suicide risk in, 530 | dsm5.pdf |
133f79e33be3-0 | 936 Index
Other hallucinogen use disorder, 523–527
associated features supporting diagnosis of,
525
comorbidity with, 527
culture-related diagnostic issues in, 526
development and course of, 525–526
diagnostic criteria for, 523–524
diagnostic features of, 524–525
diagnostic markers for, 526
differential diagnosis of, 527
functional consequences of, 527
gender-related diagnostic issues in, 526
prevalence of, 525
risk and prognostic factors for, 526
specifiers for, 524
Other health service encounters for counseling
and medical advice, 725
Other mental disorders, 707–708
other specified mental disorder, 15–16, 19,
708
other specified mental di sorder due to another
medical condition, 707
unspecified mental disorder, 15–16, 19–20, 708
unspecified mental disorder due to another
medical condition, 708
Other problems related to primary support group,
716–717
Other problems related to social environment,
724–725
Other psychosocial, personal, and environmental
circumstances, problems related to, 725
Other specified mental disorder, 15–16, 19, 708
due to another medical condition, 707
Other (or unknown) substance intoxication,
581–582
comorbidity with, 582
development and course of, 581–582
diagnostic criteria for, 581
diagnostic features of, 581
differential diagnosis of, 582
functional consequences of, 582
prevalence of, 581
Other (or unknown) substance–related disorders,
577–585
diagnoses associated with, 482 | dsm5.pdf |
133f79e33be3-1 | 577–585
diagnoses associated with, 482
other (or unknown) substance–induced
disorders, 584–585
other (or unknown) substance intoxication,
581–582
other (or unknown) substance use disorder,
577–580
other (or unknown) substance withdrawal,
583–584
unspecified other (or unknown) substance–
related disorder, 585Other (or unknown) substance use disorder,
577–580
associated features supporting diagnosis of, 579
comorbidity with, 580
culture-related diagnostic issues in, 580
development and course of, 580
diagnostic criteria for, 577–578
diagnostic features of, 579
diagnostic markers for, 580
differential diagnosis of, 580
prevalence of, 579
risk and prognostic factors for, 580
specifiers for, 578
Other (or unknown) substance withdrawal,
583–584
comorbidity with, 584
culture-related diagnostic issues in, 583
development and course of, 583
diagnostic criteria for, 583
diagnostic features of, 583
differential diagnosis of, 584
functional consequences of, 584
prevalence of, 583
Panic attacks, 189, 190, 208–209, 214–217
associated features with, 215
comorbidity with, 217
culture-related diagnostic issues in, 216
development and course of, 215–216
diagnostic markers for, 216
differential diagnosis of, 217
expected vs. unexpected, 215
features of, 214–215
functional consequences of, 217
gender-related diagnostic issues in, 216
nocturnal, 209, 215 | dsm5.pdf |
133f79e33be3-2 | gender-related diagnostic issues in, 216
nocturnal, 209, 215
in older adults, 210–211, 215–216
prevalence of, 215
risk and prognostic factors for, 216
specifier for, 214–217
suicide risk and, 215
symptoms of, 214
Panic disorder, 190, 208–214
associated features supporting diagnosis of, 210
culture-related diagnostic issues in, 211–212
development and course of, 210–211
diagnostic criteria for, 208–209
diagnostic features of, 209
diagnostic markers for, 212
differential diagnosis of, 212–213
functional consequences of, 212
gender-related diagnostic issues in, 210.212
prevalence of, 210
risk and prognostic factors for, 211
suicide risk in, 212 | dsm5.pdf |
8c139841c06c-0 | Index 937
Paranoid personality disorder, 645, 646, 649–652
associated features supporting diagnosis of,
650–651
culture-related diagnostic issues in, 651
development and course of, 651
diagnostic criteria for, 649
diagnostic features of, 649–650
differential diagnosis of, 652
prevalence of, 651
risk and prognostic factors for, 651
Paraphilic disorders, 685–705
exhibitionistic disorder, 685, 689–691
fetishistic disorder, 685, 700–702
frotteuristic disorder, 685, 691–694
highlights of changes fr om DSM-IV to DSM-5,
816
other specified para philic disorder, 705
pedophilic disorder, 685, 697–700
sexual masochism disorder, 685, 694–695
sexual sadism disorder, 685, 695–697
transvestic disorder, 685, 702–704
unspecified paraphilic disorder, 705
voyeuristic disorder, 685, 686–688
Parasomnias, 361, 399–410
nightmare disorder, 361, 404–407
non–rapid eye movement sleep arousal
disorders, 361, 399–404
rapid eye movement sleep behavior disorder,
361, 407–410
Parkinsonism
neuroleptic-induced, 709
other medication-induced, 709
Parkinson’s disease
anxiety disorders and, 203, 205, 207, 218, 221
depressive disorders and, 181, 182
major or mild neurocognitive disorder due to,
591, 604, 636–638
associated features supporting diagnosis | dsm5.pdf |
8c139841c06c-1 | 591, 604, 636–638
associated features supporting diagnosis
of, 637
comorbidity with, 638
development and course of, 637
diagnostic criteria for, 636–637
diagnostic features of, 637
diagnostic markers for, 637–638
differential diagnosis of, 638
prevalence of, 637
risk and prognostic factors for, 637
sleep-wake disorders and, 372, 383, 395, 413,
421
REM sleep behavior disorder, 361, 408, 410
Pedophilic disorder, 685, 697–700
associated features supporting diagnosis of, 698
comorbidity with, 700
development and course of, 699
diagnostic criteria for, 697–698diagnostic features of, 698
diagnostic markers for, 699
differential diagnosis of, 700
gender-related diagnostic issues in, 699
prevalence of, 698
risk and prognostic factors for, 699
Persistent complex bereavement disorder, 289,
789–792
associated features supporting diagnosis of,
791
comorbidity with, 792
culture-related diagnostic issues in, 791
development and course of, 791
diagnostic features of, 790–791
differential diagnosis of, 792
functional consequences of, 792
prevalence of, 791
proposed criteria for, 789–790
risk and prognostic factors for, 791
suicide risk in, 791
Persistent depressive disorder (dysthymia), 155,
168–171
comorbidity with, 171
development and course of, 170
diagnostic criteria for, 168–169
diagnostic features of, 169–170 | dsm5.pdf |
8c139841c06c-2 | diagnostic criteria for, 168–169
diagnostic features of, 169–170
differential diagnosis of, 170–171
functional consequences of, 170
prevalence of, 170
risk and prognostic factors for, 170
Personality change due to another medical
condition, 645, 682–684
associated features supporting diagnosis of,
683
diagnostic criteria for, 682
diagnostic features of, 683
differential diagnosis of, 683–684
subtypes of, 683
Personality disorders, 645–684
Cluster A, 646, 649–659
paranoid personality disorder, 645, 646,
649–652
schizoid personality disorder, 645, 646,
652–655
schizotypal personality disorder, 87, 89, 90,
645, 646, 655–659
Cluster B, 646, 659–672
antisocial personality disorder, 461, 476,
645, 646, 659–663
borderline personality disorder, 645, 646,
663–666
histrionic personality disorder, 645, 646,
667–669
narcissistic personality disorder, 645, 646,
669–672 | dsm5.pdf |
39ab86ff24a2-0 | 938 Index
Personality disorders (continued)
Cluster C, 646, 672–682
avoidant personality disorder, 645, 646,
672–675
dependent personality disorder, 645, 646,
675–678
obsessive-compulsive personality disorder,
645, 646, 678–682
general personality disorder, 646–649
criteria for, 646–647
culture-related diagnostic issues in, 648
development and course of, 647–648
diagnostic features of, 647
differential diagnosis of, 648–649
gender-related diagnostic issues in, 648
highlights of changes fr om DSM-IV to DSM-5,
816
other specified personality disorder, 645–646,
684
personality change due to another medical
condition, 645, 682–684
unspecified personality disorder, 645–646, 684
Personality disorders: alternative DSM-5 model,
761–781
diagnosis of, 771
general criteria for personality disorder,
761–763
Criterion A: level of personality
functioning, 762, 762
Criterion B: pathological personality traits,
762–763
Criteria C and D: pervasiveness and
stability, 763
Criteria E, F, and G: alternative
explanations for personality
pathology, 763
level of personality functioning, 762, 762,
771–772
Level of Personality Functioning Scale for
rating of, 772, 775–778
self- and interpersonal functioning
dimensional definition, 772
personality traits, 772–774
assessment of Personality Trait Model, 774
clinical utility of multidimensional
personality functioning and trait
model, 774 | dsm5.pdf |
39ab86ff24a2-1 | clinical utility of multidimensional
personality functioning and trait
model, 774
definition and description of, 772–773
definitions of personality disorder trait
domains and facets, 779–781
dimensionality of, 772–773
distinguishing traits, symptoms, and
specific behaviors, 773–774
hierarchical structure of personality, 773
Personality Trait Model, 773scoring algorithms for, 771
specific personality disorders, 763–771
antisocial personality disorder, 763, 764–765
avoidant personality disorder, 763, 765–766
borderline personality disorder, 763, 766–
767
narcissistic personality disorder, 763,
767–768
obsessive-compulsive personality disorder,
764, 768–769
personality disorder—trait specified, 761,
770–771
schizotypal personality disorder, 764,
769–770
Phencyclidine intoxication, 527–529
diagnostic criteria for, 527–528
diagnostic features of, 528
diagnostic markers for, 528
differential diagnosis of, 528–529
functional consequences of, 528
prevalence of, 528
Phencyclidine-related disorders, 481
diagnoses associated with, 482
other phencyclidine-induced disorders, 532
phencyclidine intoxication, 527–529
phencyclidine use disorder, 520–523
unspecified phencyclidine-related disorder, 533
Phencyclidine use disorder, 520–523
associated features supporting diagnosis of, 522
culture-related diagnostic issues in, 522
diagnostic criteria for, 520–521
diagnostic features of, 521–522
diagnostic markers for, 522 | dsm5.pdf |
39ab86ff24a2-2 | diagnostic features of, 521–522
diagnostic markers for, 522
differential diagnosis of, 523
functional consequences of, 522
gender-related diagnostic issues in, 522
prevalence of, 522
risk and prognostic factors for, 522
specifiers for, 521
Phobic disorders
agoraphobia, 190, 217–221
social anxiety disorder (social phobia), 190,
202–208
specific phobia, 189–190, 197–202
Physical abuse
child, 717–718
nonspouse or nonpartner, 722
spouse or partner, 720
Pica, 329–331
associated features supporting diagnosis of,
330
comorbidity with, 331
culture-related diagnostic issues in, 331
development and course of, 330
diagnostic criteria for, 329–330 | dsm5.pdf |
b2eff1a92825-0 | Index 939
diagnostic features of, 330
diagnostic markers for, 331
differential diagnosis of, 331
functional consequences of, 331
gender-related diagnostic issues in, 331
prevalence of, 330
risk and prognostic factors for, 330
Posttraumatic stress disorder (PTSD), 265, 271–280
associated features supporting diagnosis of,
276
comorbidity with, 280
culture-related diagnostic issues in, 278
development and course of, 276–277
diagnostic criteria for, 271–274
diagnostic features of, 274–276
differential diagnosis of, 279–280
functional consequences of, 278–279
gender-related diagnostic issues in, 278
prevalence of, 276
risk and prognostic factors for, 277–278
suicide risk in, 278
Postural tremor, medication-induced, 712
Premature (early) ejaculation, 423, 443–446
associated features supporting diagnosis of,
444
comorbidity with, 446
culture-related diagnostic issues in, 445
development and course of, 444–445
diagnostic criteria for, 443–444
diagnostic features of, 444
diagnostic markers for, 445
differential diagnosis of, 445–446
functional consequences of, 445
gender-related diagnostic issues in, 445
prevalence of, 444
risk and prognostic factors for, 445
Premenstrual dysphoric disorder, 155, 171–175
associated features supporting diagnosis of, 173
comorbidity with, 175
culture-related diagnostic issues in, 173
development and course of, 173
diagnostic criteria for, 171–172
diagnostic features of, 172–173 | dsm5.pdf |
b2eff1a92825-1 | diagnostic criteria for, 171–172
diagnostic features of, 172–173
diagnostic markers for, 173–174
differential diagnosis of, 174–175
functional consequences of, 174
prevalence of, 173
recording procedures for, 172
risk and prognostic factors for, 173
Principal diagnosis, 22–23
Prion disease, major or mild neurocognitive
disorder due to, 591, 604, 634–636
development and course of, 635
diagnostic criteria for, 634–635
diagnostic features of, 635diagnostic markers for, 636
differential diagnosis of, 636
prevalence of, 635
risk and prognostic factors for, 636
Problems related to access to medical and other
health care, 726
Problems related to crime or interaction with the
legal system, 725
Problems related to family upbringing, 715–716
Problems related to other psychosocial, personal,
and environmental circumstances, 725
Provisional diagnosis, 23
Pseudocyesis, 310, 327
Psychological abuse
child, 719
nonspouse or nonpartner, 722
spouse or partner abuse, 721–722
Psychological factors af fecting other medical
conditions, 309, 310, 322–324
comorbidity with, 324
culture-related diagnostic issues in, 323
development and course of, 323
diagnostic criteria for, 322
diagnostic features of, 322–323
differential diagnosis of, 323–324
functional consequences of, 323
prevalence of, 323
Psychotic disorder due to another medical
condition, 89, 115–118 | dsm5.pdf |
b2eff1a92825-2 | Psychotic disorder due to another medical
condition, 89, 115–118
associated features supporting diagnosis of, 116
comorbidity with, 118
development and course of, 117
diagnostic criteria for, 115–116
diagnostic features of, 116
diagnostic markers for, 117
differential diagnosis of, 118
functional consequences of, 118
prevalence of, 116–117
risk and prognostic factors for, 117
specifiers for, 116
suicide risk in, 118
Psychotic disorders. See Schizophrenia spectrum
and other psychotic disorders
PTSD. See Posttraumatic stress disorder
Purging disorder, 353
Pyromania, 461, 476–477
associated features supporting diagnosis of,
476–477
comorbidity with, 477
development and course of, 477
diagnostic criteria for, 476
diagnostic features of, 476
differential diagnosis of, 477
gender-related diagnostic issues in, 477
prevalence of, 477 | dsm5.pdf |
9c7aee51ad74-0 | 940 Index
Rapid eye movement (REM) sleep behavior
disorder, 361, 407–410
associated features supporting diagnosis of, 408
comorbidity with, 410
development and course of, 408–409
diagnostic criteria for, 407–408
diagnostic features of, 408
diagnostic markers for, 409
differential diagnosis of, 409–410
functional consequences of, 409
prevalence of, 408
relationship to International Classification of
Sleep Disorders, 410
risk and prognostic factors for, 409
Reactive attachment disorder, 265–268
associated features supporting diagnosis of, 266
comorbidity with, 268
culture-related diagnostic issues in, 267
development and course of, 266
diagnostic criteria for, 265–266
diagnostic features of, 266
differential diagnosis of, 267–268
functional consequences of, 267
prevalence of, 266
risk and prognostic factors for, 267
Recurrent brief depression, 183
Relational problems, 22, 715–717
other problems relate d to primary support
group, 716–717
problems related to family upbringing, 715–716
REM sleep behavior disorder. See Rapid eye
movement sleep behavior disorder
Restless legs syndrome (RLS), 361, 410–413
associated features supporting diagnosis of,
411
comorbidity with, 413
development and course of, 411–412
diagnostic criteria for, 410
diagnostic features of, 411
diagnostic markers for, 412
differential diagnosis of, 413
functional consequences of, 412–413
gender-related diagnostic issues in, 412
prevalence of, 411
relationship to International Classification of | dsm5.pdf |
9c7aee51ad74-1 | prevalence of, 411
relationship to International Classification of
Sleep Disorders, 413
risk and prognostic factors for, 412
Rett syndrome, 33, 38, 51, 53, 56, 57, 79, 80
RLS. See Restless legs syndrome
Rumination disorder, 329, 332–333
associated features supporting diagnosis of,
332–333
comorbidity with, 333
development and course of, 333
diagnostic criteria for, 332diagnostic features of, 332
differential diagnosis of, 333
functional consequences of, 333
prevalence of, 333
risk and prognostic factors for, 333
Schizoaffective disorder, 89–90, 105–110
associated features supporting diagnosis of, 107
comorbidity with, 110
culture-related diagnostic issues in, 108–109
development and course of, 108
diagnostic criteria for, 105–106
diagnostic features of, 106–107
differential diagnosis of, 109–110
functional consequences of, 109
prevalence of, 107–108
risk and prognostic factors for, 108
suicide risk in, 109
Schizoid personality disorder, 645, 646, 652–655
associated features supporting diagnosis of,
653–654
culture-related diagnostic issues in, 654
development and course of, 654
diagnostic criteria for, 652–653
diagnostic features of, 653
differential diagnosis of, 654–655
gender-related diagnostic issues in, 654
prevalence of, 654
risk and prognostic factors for, 654
Schizophrenia, 87, 99–105
associated features supporting diagnosis of, | dsm5.pdf |
9c7aee51ad74-2 | Schizophrenia, 87, 99–105
associated features supporting diagnosis of,
101–102
with catatonia, 88, 100
comorbidity with, 105
culture-related diagnostic issues in, 103
development and course of, 102–103
diagnostic features of, 87–88, 100–101
differential diagnosis of, 104–105
functional consequences of, 104
gender-related diagnostic issues in, 103–104
prevalence of, 102
risk and prognostic factors for, 103
suicide risk in, 104
Schizophrenia spectrum and other psychotic
disorders, 87–122
brief psychotic disorder, 89, 94–96
catatonia, 88, 89, 119–121
clinician-rated assessment of symptoms and
related clinical phenomena in, 89–90
delusional disorder, 89, 90–93
highlights of changes fr om DSM-IV to DSM-5,
810
key features of, 87–88
delusions, 87
disorganized thinking (speech), 88 | dsm5.pdf |
c4fd8a35eeb5-0 | Index 941
grossly disorganized or abnormal motor
behavior (including catatonia), 88
hallucinations, 87–88
negative symptoms, 88
other specified schizo phrenia spectrum and
other psychotic disorder, 122
psychotic disorder due to another medical
condition, 89, 115–118
schizoaffective disorder, 89–90, 105–110
schizophrenia, 87, 99–105
schizophreniform disorder, 89, 96–99
schizotypal (personality) disorder, 87, 89, 90
substance/medication-induced psychotic
disorder, 89, 110–115
unspecified schizophrenia spectrum and other
psychotic disorder, 122
Schizophreniform disorder, 89, 96–99
associated features supporting diagnosis of, 98
development and course of, 98
diagnostic criteria for, 96–97
diagnostic features of, 97–98
differential diagnosis of, 98–99
functional consequences of, 98
prevalence of, 98
provisional diagnosis of, 97
risk and prognostic factors for, 98
Schizotypal personality disorder, 87, 89, 90, 645,
646, 655–659
associated features supporting diagnosis of,
657
culture-related diagnostic issues in, 657
development and course of, 657
diagnostic criteria for, 655–656
diagnostic features of, 656–657
differential diagnosis of, 658–659
features and criteria in alternative DSM-5
model for personality disorders, 764,
769–770
gender-related diagnostic issues in, 658
prevalence of, 657 | dsm5.pdf |
c4fd8a35eeb5-1 | gender-related diagnostic issues in, 658
prevalence of, 657
risk and prognostic factors for, 657
Sedative, hypnotic, or an xiolytic intoxication,
556–557
associated features supporting diagnosis of, 557
diagnostic criteria for, 556
diagnostic features of, 556–557
differential diagnosis of, 557
prevalence of, 557
Sedative-, hypnotic-, or anxiolytic-related
disorders, 481, 550–560
diagnoses associated with, 482
other sedative-, hypnotic-, or anxiolytic-
induced disorders, 560
sedative, hypnotic, or anxiolytic intoxication,
556–557sedative, hypnotic, or anxiolytic use disorder,
550–556
sedative, hypnotic, or anxiolytic withdrawal,
484, 557–560
unspecified sedative-, hy pnotic-, or anxiolytic-
related disorder, 560
Sedative, hypnotic, or anxiolytic use disorder,
550–556
associated features supporting diagnosis of,
553
comorbidity with, 555–556
culture-related diagnostic issues in, 554
development and course of, 553–554
diagnostic criteria for, 550–552
diagnostic features of, 552–553
diagnostic markers for, 554–555
differential diagnosis of, 555
functional consequences of, 555
gender-related diagnostic issues in, 554
prevalence of, 553
risk and prognostic factors for, 554
specifiers for, 552
Sedative, hypnotic, or anxiolytic withdrawal, 484,
557–560 | dsm5.pdf |
c4fd8a35eeb5-2 | 557–560
associated features supporting diagnosis of, 559
diagnostic criteria for, 557–558
diagnostic features of, 558
diagnostic markers for, 559
differential diagnosis of, 559–560
prevalence of, 559
Selective mutism, 189, 195–197
associated features supporting diagnosis of,
195–196
comorbidity with, 197
culture-related diagnostic issues in, 196
development and course of, 196
diagnostic criteria for, 195
diagnostic features of, 195
differential diagnosis of, 197
functional consequences of, 196–197
prevalence of, 196
risk and prognostic factors for, 196
Separation anxiety disorder, 189, 190–195
associated features supporting diagnosis of, 192
comorbidity with, 195
culture-related diagnostic issues in, 193
development and course of, 192–193
diagnostic criteria for, 190–191
diagnostic features of, 191–192
differential diagnosis of, 194–195
functional consequences of, 193–194
gender-related diagnostic issues in, 193
prevalence of, 192
risk and prognostic factors for, 193
suicide risk in, 193 | dsm5.pdf |
2d3097fdbf72-0 | 942 Index
Severity measures, 733, 742
Clinician-Rated Dimensions of Psychosis
Symptom Severity, 742–744
frequency of use of, 742
scoring and interpretation of, 742
Sexual abuse
child, 718
nonspouse or nonpartner, 722
spouse or partner, 720
Sexual dysfunctions, 423–450
delayed ejaculation, 423, 424–426
erectile disorder, 423, 426–429
female orgasmic disorder, 423, 429–432
female sexual interest/arousal disorder, 423,
433–437
genito-pelvic pain/penetration disorder, 423,
437–440
highlights of changes fr om DSM-IV to DSM-5,
814
male hypoactive sexual desire disorder, 423,
440–443
other specified sexual dysfunction, 423, 450
premature (early) ejaculation, 423, 443–446
substance/medication-induced sexual
dysfunction, 423, 446–450
subtypes of, 423
unspecified sexual dysfunction, 423, 450
Sexual masochism disorder, 685, 694–695
associated features supporting diagnosis of, 694
comorbidity with, 695
development and course of, 695
diagnostic criteria for, 694
diagnostic features of, 694
differential diagnosis of, 695
functional consequences of, 695
prevalence of, 694
Sexual sadism disorder, 685, 695–697
associated features supporting diagnosis of, 696
comorbidity with, 697
development and course of, 697
diagnostic criteria for, 695
diagnostic features of, 696 | dsm5.pdf |
2d3097fdbf72-1 | diagnostic criteria for, 695
diagnostic features of, 696
differential diagnosis of, 697
prevalence of, 696
Shenjing shuairuo, 835–836
Shubo-kyofu, 264
Skin picking. See Excoriation (skin-picking)
disorder
Sleep-related hypoventilation, 387–390
associated features supporting diagnosis of,
387–388
comorbidity with, 389–390
development and course of, 388
diagnostic criteria for, 387
diagnostic features, 387diagnostic markers for, 389
differential diagnosis of, 389
functional consequences of, 389
gender-related diagnostic issues in, 389
prevalence of, 388
relationship to International Classification of
Sleep Disorders, 390
risk and prognostic factors for, 388
subtypes of, 387
Sleep terrors, 399–403. See also Non–rapid eye
movement sleep arousal disorders
Sleep-wake disorders, 361–422
breathing-related sleep disorders, 361, 378–390
central sleep apnea, 383–386
obstructive sleep ap nea hypopnea, 378–383
sleep-related hypoventilation, 387–390
circadian rhythm sleep-wake disorders, 361,
390–398
advanced sleep phase type, 393–394
delayed sleep phase type, 391–392
irregular sleep-wake type, 394–396
non-24-hour sleep-wake type, 396–397
shift work type, 397–398
highlights of changes fr om DSM-IV to DSM-5,
814
hypersomnolence disorder, 361, 368–372
other specified, 421 | dsm5.pdf |
2d3097fdbf72-2 | other specified, 421
unspecified, 421
insomnia disorder, 361, 362–368
other specified, 420
unspecified, 420–421
narcolepsy, 361, 372–378
other specified sleep-wake disorder, 421
parasomnias, 399–410
nightmare disorder, 361, 404–407
non–rapid eye movement sleep arousal
disorders, 361, 399–404
rapid eye movement sleep behavior
disorder, 361, 407–410
relationship to International Classification of
Sleep Disorders, 361–362 ( See also specific
sleep-wake disorders )
restless legs syndrome, 361, 410–413
substance/medication-induced sleep disorder,
413–420
unspecified sleep-wake disorder, 422
Sleepwalking, 399–403. See also Non–rapid eye
movement sleep arousal disorders
Smoking. See Tobacco-related disorders
Social anxiety disorder (social phobia), 190,
202–208
associated features supporting diagnosis of,
204
comorbidity with, 208
culture-related diagnostic issues in, 205–206 | dsm5.pdf |
eef782649831-0 | Index 943
development and course of, 205
diagnostic criteria for, 202–203
diagnostic features of, 203–204
differential diagnosis of, 206–207
functional consequences of, 206
gender-related diagnostic issues in, 204, 206
prevalence of, 204
risk and prognostic factors for, 205
specifiers for, 203
Social (pragmatic) communication disorder, 31,
47–49
associated features supporting diagnosis of, 48
development and course of, 48
diagnostic criteria for, 47–48
diagnostic features of, 48
differential diagnosis of, 49
risk and prognostic factors for, 48
Somatic symptom disorder, 309, 310, 311–315
associated features supporting diagnosis of,
312
comorbidity with, 314–315
culture-related diagnostic issues in, 313
development and course of, 312–313
diagnostic criteria for, 311
diagnostic features of, 311–312
differential diagnosis of, 314
prevalence of, 312
risk and prognostic factors for, 313
Somatic symptoms and related disorders, 309–327
conversion disorder (functional neurological
symptom disorder), 309, 310, 318–321
factitious disorder, 309, 310, 324–326
highlights of changes fr om DSM-IV to DSM-5,
812–813
illness anxiety disorder, 309, 310, 315–318
other specified somatic symptom and related
disorder, 309, 310, 327
psychological factors affecting other medical
conditions, 309, 310, 322–324 | dsm5.pdf |
eef782649831-1 | conditions, 309, 310, 322–324
somatic symptom disorder, 309, 310, 311–315
unspecified somatic symptom and related
disorder, 309, 310, 327
Specific learning disorder, 32, 66–74
associated features supporting diagnosis of, 70
comorbidity with, 72, 74
culture-related diagnostic issues in, 72–73
development and course of, 70–72
diagnostic criteria for, 66–68
diagnostic features of, 68–70
differential diagnosis of, 73–74
functional consequences of, 73
gender-related diagnostic issues in, 73
prevalence of, 70
recording procedures for, 68
risk and prognostic factors for, 72Specific phobia, 189–190, 197–202
associated features supporting diagnosis of, 199
comorbidity with, 202
culture-related diagnostic issues in, 201
development and course of, 199–200
diagnostic criteria for, 197–198
diagnostic features of, 198–199
differential diagnosis of, 201–202
functional consequences of, 201
prevalence of, 199
risk and prognostic factors for, 200
specifiers for, 198
suicide risk in, 201
Specifiers, 21–22
Specifiers for bipolar and related disorders,
149–154
Specifiers for depressive disorders, 184–188
Speech sound disorder, 31, 44–45
associated features supporting diagnosis of, 44
development and course of, 44–45
diagnostic criteria for, 44
diagnostic features of, 44
differential diagnosis of, 45
Spouse or partner abuse, psychological, 721–722 | dsm5.pdf |
eef782649831-2 | Spouse or partner abuse, psychological, 721–722
Spouse or partner neglect, 721
Spouse or partner violence
physical, 720
sexual, 720
Stereotypic movement disorder, 32, 77–80
comorbidity with, 80
culture-related diagnostic issues in, 79
development and course of, 79
diagnostic criteria for, 77–78
diagnostic features of, 78–79
differential diagnosis of, 79–80
prevalence of, 79
recording procedures for, 78
risk and prognostic factors for, 79
specifiers for, 78
Stimulant intoxication, 567–569
associated features supporting diagnosis of, 568
diagnostic criteria for, 567–568
diagnostic features of, 568
differential diagnosis of, 568–569
Stimulant-related disorders, 481, 561–570
diagnoses associated with, 482
other stimulant-indu ced disorders, 570
stimulant intoxication, 567–569
stimulant use disorder, 561–567
stimulant withdrawal, 484, 569–570
unspecified stimulant-related disorder, 570
Stimulant use disorder, 561–567
associated features supporting diagnosis of,
563–564
comorbidity with, 566–567 | dsm5.pdf |
162bdb5e8349-0 | 944 Index
Stimulant use disorder (continued)
culture-related diagnostic issues in, 565
development and course of, 564–565
diagnostic criteria for, 561–562
diagnostic features of, 563
diagnostic markers for, 565–566
differential diagnosis of, 566
functional consequences of, 566
prevalence of, 564
risk and prognostic factors for, 565
specifiers for, 563
Stimulant withdrawal, 484, 569–570
associated features supporting diagnosis of, 570
diagnostic criteria for, 569
differential diagnosis of, 570
Stroke, 46, 73, 117
bipolar disorder and, 146, 147
depressive disorders and, 164, 167, 181–182
Stuttering. See Childhood-onset fluency disorder
(stuttering)
Substance-induced disorders, 481, 485–490. See
also specific substances of abuse
alcohol-related, 497–503
caffeine-related, 503–508
cannabis-related, 516–519
hallucinogen-related, 527–533
inhalant-related, 538–540
opioid-related, 546–549
other (or unknown) substance–related, 581–585
sedative-, hypnotic-, or anxiolytic-related,
556–560
substance intoxication and withdrawal, 481,
485–487 ( See also Intoxication;
Withdrawal from substance)
associated with use of multiple substances,
486
development and course of, 487
duration of effects and, 486
laboratory findings associated with,
486–487
recording procedures for, 487
related to route of administration and | dsm5.pdf |
162bdb5e8349-1 | 486–487
recording procedures for, 487
related to route of administration and
speed of substance effects, 486
substance/medication-induced mental
disorders, 481, 487–490
development and course of, 489
features of, 488–489
functional consequences of, 490
recording procedures for, 490
tobacco-related, 575–576
Substance intoxication delirium, 596–597, 598
Substance/medication-ind uced anxiety disorder,
190, 226–230
associated features supporting diagnosis of,
228–229diagnostic criteria for, 226–227
diagnostic features of, 228
diagnostic markers for, 229
differential diagnosis of, 229–230
prevalence of, 229
recording procedures for, 227–228
Substance/medication-induced bipolar and
related disorder, 123, 142–145
associated features supporting diagnosis of, 144
comorbidity with, 146
development and course of, 144–145
diagnostic criteria for, 142–143
diagnostic features of, 144
diagnostic markers for, 145
differential diagnosis of, 145
prevalence of, 144
recording procedures for, 143–144
Substance/medication-induced depressive
disorder, 155, 175–180
comorbidity with, 180
development and course of, 178
diagnostic criteria for, 175–176
diagnostic features of, 177–178
diagnostic markers for, 179
differential diagnosis of, 179–180
prevalence of, 178
recording procedures for, 176–177
risk and prognostic factors for, 178–179 | dsm5.pdf |
162bdb5e8349-2 | risk and prognostic factors for, 178–179
suicide risk in, 179
Substance/medication-induced neurocognitive
disorder, 591, 603, 627–632
associated features supporting diagnosis of, 630
comorbidity with, 632
development and course of, 631
diagnostic criteria for, 627–629
diagnostic features of, 629–630
diagnostic markers for, 631
differential diagnosis of, 631
functional consequences of, 631
prevalence of, 630
recording procedures for, 629
risk and prognostic factors for, 631
Substance/medication-induced obsessive-
compulsive and related disorder, 235, 236,
257–260
associated features supporting diagnosis of, 259
diagnostic criteria for, 257–258
diagnostic features of, 259
differential diagnosis of, 259–260
prevalence of, 259
recording procedures for, 258–259
Substance/medication-induced psychotic
disorder, 89, 110–115
associated features supporting diagnosis of, 113
development and course of, 114 | dsm5.pdf |
699a2340ba99-0 | Index 945
diagnostic criteria for, 110–111
diagnostic features of, 112–113
diagnostic markers for, 114
differential diagnosis of, 114–115
functional consequences of, 114
prevalence of, 113
recording procedures for, 112
Substance/medication-induced sexual
dysfunction, 423, 446–450
associated features supporting diagnosis of,
448–449
culture-related diagnostic issues in, 449
development and course of, 449
diagnostic criteria for, 446–447
diagnostic features of, 448
differential diagnosis of, 450
functional consequences of, 450
gender-related diagnostic issues in, 449
prevalence of, 449
recording procedures for, 447–448
Substance/medication-ind uced sleep disorder,
413–420
associated features supporting diagnosis of,
416–418
comorbidity with, 420
culture-related diagnostic issues in, 418
development and course of, 418
diagnostic criteria for, 413–415
diagnostic features of, 416
diagnostic markers for, 419
differential diagnosis of, 419–420
functional consequences of, 419
gender-related diagnostic issues in, 418
recording procedures for, 415–416
relationship to International Classification of
Sleep Disorders, 420
risk and prognostic factors for, 418
Substance-related and addictive disorders,
481–589
gambling disorder, 481, 585–589
highlights of changes fr om DSM-IV to DSM-5,
815
substance-related disorders, 481–585 ( See also
specific substances of abuse )
alcohol-related disorders, 490–503
caffeine-related disorders, 503–509 | dsm5.pdf |
699a2340ba99-1 | alcohol-related disorders, 490–503
caffeine-related disorders, 503–509
cannabis-related disorders, 509–519
diagnoses associated with substance class,
482
drug classes in, 481
hallucinogen-related disorders, 520–533
inhalant-related disorders, 533–540
opioid-related disorders, 540–550
other (or unknown) substance–related
disorders, 577–585sedative-, hypnotic- or anxiolytic-related
disorders, 550–560
stimulant-related disorders, 561–570
substance-induced disorders, 481, 485–490
substance use disorders, 481, 483–485,
490–585
tobacco-related disorders, 571–577
Substance use disorders, 481, 483–485
alcohol use disorder, 490–497
caffeine use disorder, 792–795
cannabis use disorder, 509–516
features of, 483–484
inhalant use disorder, 533–538
opioid use disorder, 541–546
other hallucinogen use disorder, 523–527
other (or unknown) substance use disorder,
577–580
phencyclidine use disorder, 520–523
recording procedures for, 485
sedative, hypnotic, or anxiolytic use disorder,
550–556
severity and specifiers for, 484
stimulant use disorder, 561–567
tobacco use disorder, 571–574
tolerance and withdrawal in, 484
Substance withdrawal delirium, 597, 598–599
Suicidal behavior disorder, 801–803
comorbidity with, 803
culture-related diagnostic issues in, 802 | dsm5.pdf |
699a2340ba99-2 | comorbidity with, 803
culture-related diagnostic issues in, 802
development and course of, 802
diagnostic features of, 801–802
diagnostic markers for, 802
functional consequences of, 802
proposed criteria for, 801
specifiers for, 801
Suicide risk
anorexia nervosa and, 343
bipolar I disorder and, 131
bipolar II disorder and, 138
body dysmorphic disorder and, 245
bulimia nervosa and, 349
depressive disorder due to another medical
condition and, 182
depressive episodes with short-duration
hypomania and, 788
disruptive mood dysregulation disorder and,
158
dissociative amnesia and, 300
dissociative identity disorder and, 295
major depressive disorder and, 164, 167
neurobehavioral disorder associated with
prenatal alcohol exposure and, 800
obsessive-compulsive disorder and, 240
opioid use disorder and, 544
other hallucinogen intoxication and, 530 | dsm5.pdf |
de293eff5eda-0 | 946 Index
Suicide risk (continued)
panic attacks and, 215
panic disorder and, 212
persistent complex bereavement disorder and,
791
posttraumatic stress disorder and, 278
psychotic disorder due to another medical
condition and, 118
schizoaffective disorder and, 109
schizophrenia and, 104
separation anxiety disorder and, 193
specific phobia and, 201
substance/medication-induced depressive
disorder and, 180
Susto, 836–837
Taijin kyofusho, 205, 837
Tardive akathisia, 712
Tardive dyskinesia, 22, 712
Tardive dystonia, 712
Technical terms, glossary of, 817–831
Tic disorders, 32, 81–85
comorbidity with, 83, 85
culture-related diagnostic issues in, 83
development and course of, 83
diagnostic criteria for, 81
diagnostic features of, 81–82
differential diagnosis of, 84
functional consequences of, 84
gender-related diagnostic issues in, 83, 84
other specified tic disorder, 85
prevalence of, 83
risk and prognostic factors for, 83
specifiers for, 81
unspecified tic disorder, 85
Tobacco-related disorders, 481, 571–577
diagnoses associated with, 482
other tobacco-induced disorders, 576
tobacco use disorder, 571–574
tobacco withdrawal, 484, 575–576
unspecified tobacco-related disorder, 577
Tobacco use disorder, 571–574
associated features supporting diagnosis of, 573
comorbidity with, 574 | dsm5.pdf |
de293eff5eda-1 | associated features supporting diagnosis of, 573
comorbidity with, 574
culture-related diagnostic issues in, 574
development and course of, 573
diagnostic criteria for, 571–572
diagnostic features of, 572–573
diagnostic markers for, 574
functional consequences of, 574
prevalence of, 573
risk and prognostic factors for, 573–574
specifiers for, 572
Tobacco withdrawal, 484, 575–576
associated features supporting diagnosis of, 575development and course of, 576
diagnostic criteria for, 575
diagnostic features of, 575
diagnostic markers for, 576
differential diagnosis of, 576
functional consequences of, 576
prevalence of, 576
risk and prognostic factors for, 576
Tolerance to substance effects, 484
Tourette’s disorder, 32. See also Tic disorders
diagnostic criteria for, 81
diagnostic features of, 81–82
functional consequences of, 84
prevalence of, 83
risk and prognostic factors for, 83
Transvestic disorder, 685, 702–704
associated features supporting diagnosis of,
703
comorbidity with, 704
development and course of, 703–704
diagnostic criteria for, 702
diagnostic features of, 703
differential diagnosis of, 704
functional consequences of, 704
prevalence of, 703
specifiers for, 703
Trauma- and stressor-related disorders, 265–290
acute stress disorder, 265, 280–286
adjustment disorders, 265, 286–289
disinhibited social engagement disorder, 265,
268–270 | dsm5.pdf |
de293eff5eda-2 | disinhibited social engagement disorder, 265,
268–270
highlights of changes fr om DSM-IV to DSM-5,
812
other specified trauma- and stressor-related
disorder, 289
posttraumatic stress disorder, 265, 271–280
reactive attachment disorder, 265–268
unspecified trauma- and stressor-related
disorder, 290
Traumatic brain injury
bipolar disorder and, 146
depressive disorders and, 181
dissociative amnesia and, 298, 299, 301
hoarding disorder and, 247, 250
major or mild neurocognitive disorder due to,
591, 603, 624–627, 626
associated features supporting diagnosis
of, 625
comorbidity with, 627
development and course of, 625–626
diagnostic criteria for, 624
diagnostic features of, 625
diagnostic markers for, 627
differential diagnosis of, 627
functional consequences of, 627 | dsm5.pdf |